

Published in final edited form as:

*Prog Brain Res.* 2007 ; 160: 21–41. doi:10.1016/S0079-6123(06)60003-4.

## GABA<sub>A</sub> receptors:

### structure and function in the basal ganglia

T. Goetz<sup>1</sup>, A. Arslan<sup>1</sup>, W. Wisden<sup>2</sup>, and P. Wulff<sup>1,\*</sup>

<sup>1</sup>Department of Clinical Neurobiology, University of Heidelberg, Im Neuenheimer Feld 364, 69120 Heidelberg, Germany

<sup>2</sup>Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, Scotland, UK

### Abstract

$\gamma$ -Aminobutyric acid type A (GABA<sub>A</sub>) receptors, the major inhibitory neurotransmitter receptors responsible for fast inhibition in the basal ganglia, belong to the superfamily of “cys-cys loop” ligand-gated ion channels. GABA<sub>A</sub> receptors form as pentameric assemblies of subunits, with a central Cl<sup>-</sup> permeable pore. On binding of two GABA molecules to the extracellular receptor domain, a conformational change is induced in the oligomer and Cl<sup>-</sup>, in most adult neurons, moves into the cell leading to an inhibitory hyperpolarization. Nineteen mammalian subunit genes have been identified, each showing distinct regional and cell-type-specific expression. The combinatorial assembly of the subunits generates considerable functional diversity. Here we place the focus on GABA<sub>A</sub> receptor expression in the basal ganglia: striatum, globus pallidus, substantia nigra and subthalamic nucleus, where, in addition to the standard  $\alpha 1\beta 2/3\gamma 2$  receptor subtype, significant levels of other subunits ( $\alpha 2$ ,  $\alpha 3$ ,  $\alpha 4$ ,  $\gamma 1$ ,  $\gamma 3$  and  $\delta$ ) are expressed in some nuclei.

### Keywords

GABA; GABA<sub>A</sub> receptor; basal ganglia; striatum; globus pallidus; substantia nigra; benzodiazepines

---

GABA<sub>A</sub> receptors are essential for the function of the entire basal ganglia network, providing fast (millisecond) synaptic as well as tonic extrasynaptic inhibition within and between the various basal ganglia nuclei (reviewed in Smith et al., 1998; Misgeld, 2004; Tepper and Bolam, 2004). As for other brain regions, different neuronal subtypes within the basal ganglia employ different GABA<sub>A</sub> receptor subtypes. Here we first review the genetics and structure of GABA<sub>A</sub> receptor subtypes; we then consider key drugs that act on the receptors to enhance or decrease GABA's actions; finally, we summarize which receptor subunit combinations are expressed in the various nuclei of the basal ganglia.

GABA<sub>A</sub> receptors are GABA-gated anion channels responsible (together with ligand-gated glycine receptors) for most fast inhibitory synaptic transmission in the vertebrate central nervous system. GABA<sub>A</sub> receptors are permeable to HCO<sub>3</sub><sup>-</sup> and Cl<sup>-</sup> ions; the permeability ratio of HCO<sub>3</sub><sup>-</sup>/Cl<sup>-</sup> is approximately 0.2 to 0.4 (reviewed in Kaila et al., 1997). HCO<sub>3</sub><sup>-</sup> moves out of the cell causing a mild depolarization (the reversal potential for HCO<sub>3</sub><sup>-</sup> is -12 mV). In mature neurons Cl<sup>-</sup> usually moves into the cell overriding this mild depolarization, causing a strong inhibitory hyperpolarization, as the Cl<sup>-</sup> reversal potential is 15-20 mV more

negative than the resting membrane potential. The  $\text{Cl}^-$  gradient is maintained by K-Cl co-transporters (Rivera et al., 2005). Depending on the intracellular  $\text{Cl}^-$  concentration,  $\text{GABA}_A$  receptor activation can also lead to  $\text{Cl}^-$  efflux and depolarization. This is the case, for example, during embryonic and early postnatal development when K-Cl co-transporters are not expressed at sufficient levels to efficiently transport  $\text{Cl}^-$  out of the cell (Rivera et al., 2005). There are interesting caveats: adult dopaminergic neurons in the substantia nigra pars compacta have little KCC2 expression (Gulasci et al., 2003), possibly explaining the relatively low efficacy of  $\text{GABA}_A$  receptor-mediated inhibition in nigral dopaminergic neurons (Gulasci et al., 2003). Further, KCC2 expression can vary in subdomains of neurons, thus affecting local  $\text{Cl}^-$  gradients. KCC2 is absent from the axon initial segments of neocortical pyramidal cells (Szabadics et al., 2006). Thus  $\text{GABA}_A$  terminals arriving at this location may produce depolarization via  $\text{GABA}_A$  receptors in this context. In hippocampal neurons the dendritic KCC2 channels can also be transiently inhibited by  $\text{Ca}^{2+}$  entry through voltage-gated  $\text{Ca}^{2+}$  channels, thus producing local changes in the dendritic  $\text{Cl}^-$  gradient and affecting the efficacy of  $\text{GABA}_A$  receptor inhibition, and possibly inducing plasticity at  $\text{GABA}_A$  synapses (Fiumelli et al., 2005). This is a potential mechanism to bear in mind when considering  $\text{GABA}_A$  function in the basal ganglia.

### **$\text{GABA}_A$ receptors: genes**

In mammals,  $\text{GABA}_A$  receptors form as heteropentameric assemblies from a family of 19 subunits encoded by distinct genes ( $\alpha 1$ - $\alpha 6$ ,  $\beta 1$ - $\beta 3$ ,  $\gamma 1$ - $\gamma 3$ ,  $\delta$ ,  $\epsilon$ ,  $\theta$ ,  $\pi$  and  $\rho 1$ - $\rho 3$ ) (Korpi et al., 2002a; Rudolph and Moehler, 2006; Whiting, 2006). Depending on the subunit composition  $\text{GABA}_A$  receptors differ in their biophysical properties and affinity for GABA (see Section “ $\text{GABA}_A$  receptors: how subunit combinations affect synaptic and extrasynaptic transmission” below), their pharmacology (see Section “ $\text{GABA}_A$  receptor agonists, antagonists and allosteric modulators” below) and location on the cell (see Section “Extrasynaptic  $\text{GABA}_A$  receptors:  $\alpha 4\beta\delta$  subtype” below). Along with the closely related glycine receptors,  $\text{GABA}_A$  receptors were originally cloned by the classical tour-de-force method: peptide sequences obtained from purified (bovine brain) receptors were used to construct synthetic DNA probes to screen brain cDNA libraries (Grenningloh et al., 1987; Schofield et al., 1987). This was the starting point. Within a few years, this now historical technique of screening cDNA libraries had revealed most of the gene family, all the  $\alpha 1$ - $\alpha 6$ ,  $\beta 1$ - $\beta 3$ ,  $\gamma 1$ - $\gamma 3$  subunits and one  $\delta$  subunit (Seeburg et al., 1990); over the remaining decade, a few more subunits, such as  $\epsilon$ ,  $\theta$  and  $\pi$  were characterized (Davies et al., 1997; Hedblom and Kirkness, 1997; Bonnert et al., 1999; Sinkkonen et al., 2000). With the completion of the human genome database, Simon et al. (2004) did an *in silico* hybridization screen, searching for further undescribed mammalian  $\text{GABA}_A$  receptor genes but found none. Most of the subunit gene family members are in clusters (Simon et al., 2004), suggesting gene and then cluster duplication during the evolutionary origin of vertebrates:  $\beta 2$ ,  $\alpha 6$ ,  $\alpha 1$ ,  $\gamma 2$  form a cluster in that order on human chromosome 5q34; the  $\beta 3$ ,  $\alpha 5$ ,  $\gamma 3$  genes cluster in that order on human chromosome 15q13; the  $\gamma 1$ ,  $\alpha 2$ ,  $\alpha 4$ ,  $\beta 1$  genes cluster in that order on chromosome 4p12; the  $\epsilon$ ,  $\alpha 3$ ,  $\theta$  genes cluster in that order on Xq28; the  $\rho 1$  and  $\rho 2$  genes are 40 Kb apart on 6q15; the  $\pi$ ,  $\rho 3$  and  $\delta$  subunit genes are isolated on human chromosomes 5q35.1, 3q12.1 and 1p36.3 respectively (Simon et al., 2004). The complete genome data makes it an easy task to see the gene cluster organizations at a few keyboard strokes ([http://www.ensembl.org/Homo\\_sapiens/index.html](http://www.ensembl.org/Homo_sapiens/index.html)).

As determined by both *in situ* hybridization (mRNA localization) with gene-specific probes and immunocytochemistry (protein localization) with subunit-specific antibodies, the expression of the individual subunit genes is age- and region-specific (Laurie et al., 1992a, b; Wisden et al., 1992; Fritschy and Mohler, 1995; Schwarzer et al., 2001). Some  $\text{GABA}_A$  receptor subunit genes have extremely restricted expression patterns; the  $\alpha 6$  subunit gene

expresses only in cerebellar and cochlear nucleus granule cells (Luddens et al., 1990), the  $\rho$  subunit genes are mainly expressed in retina with low transcript levels in the hippocampus and colliculi — these receptors, because of their unique pharmacology used to be termed as “GABA<sub>C</sub>”; the  $\pi$  gene is expressed in non-neural tissues (Hedblom and Kirkness, 1997). The  $\epsilon$  and  $\theta$  subunit genes are mainly transcribed in the locus ceruleus (the adrenergic nucleus in the brainstem), dorsal raphe (serotonergic cells) and cholinergic cells (Sinkkonen et al., 2000; Moragues et al., 2002).

The clustering of the GABA<sub>A</sub> receptor subunit genes raises the question of whether the clustered genes are co-regulated. The  $\alpha 1$  and  $\beta 2$  genes do indeed share identical transcription patterns, nucleus for nucleus and even have the same RNA levels in each area (Wisden et al., 1992; Duncan et al., 1995); thus these two genes may share regulatory elements. All the other subunit genes have sometimes common, sometimes divergent expression patterns, with no correlation with which gene is in which cluster. The expression of the GABA<sub>A</sub> receptor genes in the basal ganglia is reviewed in the Section “Expression of GABA<sub>A</sub> receptor subunit genes in the basal ganglia” below.

### GABA<sub>A</sub> receptor structure

The GABA<sub>A</sub> receptor belongs to a superfamily of ligand-gated ion channels (“Cys-loop receptors”) that in vertebrates include the nicotinic acetylcholine receptors (nAChR), the 5-hydroxytryptamine type 3 (5-HT<sub>3</sub>) receptors, the zinc-activated ion channel (ZAC) and the glycine receptors (reviewed in Cromer et al., 2002; Lester et al., 2004; Peters et al., 2005; Unwin, 2005). In imagining how the GABA<sub>A</sub> receptor must look, we can do no better than quote Unwin (2005) for his empirical observations on the *Torpedo* nicotinic acetylcholine receptor: “The receptor (a large 290 kDa glycoprotein) is composed of elongated subunits, which associate with their long axes approximately normal to the membrane, creating a continuous wall around the central ion-conducting path. The whole assembly presents a rounded, nearly fivefold symmetric assembly when viewed from the synaptic cleft, but is wedge-shaped when viewed parallel with the membrane plane. All the subunits of the receptor have a similar size 30Å × 40Å × 160 Å and the same three-dimensional fold. Each subunit is a three-domain protein and so portions the channel naturally into its ligand-binding, membrane-spanning and intracellular parts” (Unwin, 2005).

In GABA<sub>A</sub> receptors, the arrangement of subunits around the channel is probably  $\gamma\beta\alpha\beta\alpha$  counter-clockwise when viewed from the extracellular space (Baumann et al., 2002). Current thinking is that for those cells in which they are expressed,  $\epsilon$  and  $\pi$  subunits can replace the  $\gamma$  and  $\delta$  subunit within the pentamer, whereas the  $\theta$  subunit might replace a  $\beta$  subunit (Sieghart and Sperk, 2002). As for all members of the nicotinic receptor superfamily, all GABA<sub>A</sub> receptor subunits contain a large extracellular N-terminal domain of approximately 200 amino acids shaped by a cysteine disulfide bridge (the so-called “Cys-loop”). For GABA<sub>A</sub> subunits, the amino acid consensus sequence of the Cys-loop is C\*\*\*\*\*F/YP\*D\*\*\*C\*\*\*\*\*S (where \* is a degenerate residue; Simon et al., 2004).

Each subunit contains four predicted transmembrane spanning domains (TM1 to TM4) of about 20 amino acids and a large intracellular loop between TM3 and TM4 (TM3-TM4 loop) (Fig. 1) (Macdonald and Haas, 2000). Many GABA<sub>A</sub> receptor subunits have the amino acid sequence (TTVLTMTT) in the TM2 domain (Seeburg et al., 1990). Five of these eight amino acids have been proposed to line the ion channel. TM1, TM3 and TM4 segregate TM2 from membrane lipid (Unwin, 2005). The amino acids specifying that the nicotinic receptors gate cations have been identified. The selectivity filter and gate lies at the intracellular end of the TM2 domains and includes part of the TM1-TM2 loop. Mutating these amino acids in the  $\alpha 7$  subunit of homomeric nicotinic receptors produced

acetylcholine-gated anion channels (Galzi et al., 1992). The converse can also be done: mutation of five amino acids in the TM1-TM2 loop of the GABA<sub>A</sub> receptor  $\beta$ 3 subunit to the corresponding amino acids of the  $\alpha$ 7 nicotinic acetylcholine subunit produces cation-selective GABA<sub>A</sub> receptors (Jensen et al., 2002). Similar mutations in the  $\alpha$ 2 or  $\gamma$ 2 subunits did not change ion selectivity. Thus the  $\beta$  subunits predominantly determine the ion selectivity of the GABA<sub>A</sub> receptor (Jensen et al., 2002).

In the 5-HT<sub>3</sub> and nicotinic receptors, residues in the TM3-TM4 loop region influence single channel conductance (Peters et al., 2005; Hales et al., 2006). The TM3-TM4 loop, which may be relatively unstructured in the nAChR (Kukhtina et al., 2006), contributes key sites for attaching anchor and regulatory proteins involved in locating the receptor at synapses and in governing the activity of GABA<sub>A</sub> receptors (Kittler and Moss, 2003) (see Sections “Synaptic GABA<sub>A</sub> receptors:  $\alpha\beta\gamma$  subunit combinations and anchoring role of the  $\gamma$ 2 subunit and gephyrin” and “Regulation of GABA<sub>A</sub> receptor function by neuromodulators: the role of kinases and phosphatases”). But the TM4 region of the  $\gamma$ 2 subunit is necessary and sufficient to confer a synaptic localization on the receptor (Alldred et al., 2005).

The atomic structure of a GABA<sub>A</sub> receptor subunit complex has not so far been solved directly. Instead, realistic models have used the empirically determined structural coordinates of the muscle nicotinic acetylcholine receptor from the electric organ of the *Torpedo* ray fish and a related snail acetylcholine receptor binding protein (AChBP) (Brejc et al., 2001; Cromer et al., 2002; Ernst et al., 2003; Unwin, 2003, 2005). The AChBP shows sequence similarity with the N-terminus of the nAChR at regions that build the agonist-binding sites; the AChBP contains a Cys-loop but lacks the transmembrane domains. It assembles as soluble homopentamers (Brejc et al., 2001). The crystal structure of the AChBP, with bound ligand, provided a template for comparative modelling of the N-terminal extracellular domain of GABA<sub>A</sub> receptors (Ernst et al., 2003), whereas Unwin’s most recent structure of the *Torpedo* nAChR at 4 Å resolution obtained by cryo-EM, and incorporating insights from the AChBP, has given a full-scale atomic model (Protein Data Bank Code 2BG9). According to Xiu and colleagues, 2BG9 represents a substantial advance for the field, and all modern attempts to obtain molecular scale information on the structure and function of Cys-loop receptors must consider this as a starting point (Xiu et al., 2005; Unwin, 2005). 2BG9 provides us with a view of how the entire GABA<sub>A</sub> receptor must look, including the transmembrane and large cytoplasmic loops (Unwin, 2003, 2005).

Before 2BG9, modellers used family conservation patterns and fold predictions to estimate that 60-75% of the amino acid residues of the GABA<sub>A</sub> receptor subunits have structural equivalents in the AChBP template (Ernst et al., 2003). The accuracy of the GABA<sub>A</sub> receptor model will be limited in regions where alignment is unclear (e.g., due to low sequence identity) or in regions where the AChBP differs from other family members due to its soluble, non-membrane-bound nature (Ernst et al., 2003). A model of the extracellular domain of a pentameric GABA<sub>A</sub> receptor consisting of two  $\alpha$ , two  $\beta$  and one  $\gamma$ 2 subunit is shown in Fig. 2. In this model the amino acids known to contribute to ligand-binding sites and interfaces are correctly positioned and the interface-forming segments and the solvent accessibility of individual residues correlate well with experimental data (Ernst et al., 2003). Six “loops” (loop A, B, C for the plus side and D, E, F for the minus side) at the interface between neighbouring subunits form the ligand-binding sites (Sigel and Buhr, 1997; Olsen et al., 2004). The binding pocket for GABA forms at the interface between the  $\alpha$  and the  $\beta$  subunit (Figs. 2a, c, d), the binding pocket for benzodiazepines lies at the interface of the  $\alpha$  and the  $\gamma$  subunit (Figs. 2a, b). The predicted space for agonist binding is formed by loops A, B, C, D and E (blue volume in Fig. 2d) and correlates with experimental data from photolabeling of  $\alpha$ 1F64 by [<sup>3</sup>H]muscimol and substituted cysteine accessibility mapping (Ernst et al., 2003; Olsen et al., 2004). Amino acid residues on loops A, B, C, D and E at the

interface of the  $\alpha$  and the  $\gamma$  subunit influence binding, potency and efficacy of benzodiazepines (see Section “GABA<sub>A</sub> receptors: allosteric modulation by benzodiazepines and related ligands”) (Fig. 2b) (Ernst et al., 2003). The predicted benzodiazepine pocket is larger than the GABA pocket. It communicates with the Cys-loop of the  $\alpha$  subunit and extends down to the membrane-near part, which possibly contains side chains from the linker between transmembrane region 2 and 3 of the  $\alpha$  subunit (Ernst et al., 2003).

## GABA<sub>A</sub> receptor gating by agonist

As for all other ligand-gated channels, GABA<sub>A</sub> receptors convert chemical messages into electrical signals. In less than a millisecond, the binding of two (tiny) molecules of GABA between the  $\alpha$  and  $\beta$  subunits induces a conformational change in the (giant) receptor oligomer that opens the central ion channel (see Baumann et al., 2003). This remarkable process is called “gating”. In the opinion of Xiu et al. (2005), “the gating mechanism for the Cys-loop superfamily is one of the most challenging questions in molecular neuroscience”. The full 2BG9 model of the nAChR suggests ways in which the agonist-binding site couples to the transmembrane region and initiates gating; principles applying to the nAChR are likely to apply, with minor variations, to other members of the superfamily (Unwin, 2005).

The basis for a model of how gating works is that specific ion pairs exert precise control over gating (Kash et al., 2003; Xiu et al., 2005). The membrane-near location of two flexible loops, loop 2 and loop 7 (the Cys-loop) in the crystal structure of the AChBP suggested an involvement in gating of the Cys-loop in the GABA<sub>A</sub> receptor. Indeed, Kash et al. (2003) using an “ion pair model”, found by site-directed mutagenesis in the  $\alpha 1$  subunit that optimal gating needs electrostatic interactions between negatively charged residues in loops 2 and 7 (Asp57 and Asp 149) and a positively charged residue in the region linking transmembrane domains 2 and 3 (Lys 279). For the  $\beta 2$  subunit of the GABA<sub>A</sub> receptor the interaction between an acidic residue in loop 7 (Asp 146) and a basic residue in pre-transmembrane domain-1 (Lys 215) helps couple agonist binding to channel gating (Kash et al., 2004). Studies on other members of the “Cys-loop” family found residues at corresponding regions in the nicotinic acetylcholine receptor and the serotonin 5-HT<sub>3</sub> receptor as critical coupling elements for gating (Lee and Sine, 2005; Lummis et al., 2005). Nevertheless, building on the results of Kash and colleagues in a detailed and broad examination of electrostatic interactions in the subunits, Xiu et al. (2005) concluded that no specific ion pair interaction in fact influences gating, but instead a cluster of charges is important; specific ion pair interactions are non-essential and it is misleading to focus only on specific residues: “Receptors have evolved to create a compatible collection of charged residues that allows the receptor to assemble and also facilitates the existence of and interconversions among multiple states” (Xiu et al., 2005).

## Subunit assembly rules for GABA<sub>A</sub> receptors

The GABA<sub>A</sub> receptor subunit combinations found in brain are partly governed by which cell types express which genes (e.g., Wisden et al., 1992) and partly by preferential partnering of subunits within a given cell (e.g., Jones et al., 1997); for example, the  $\alpha 4$  and  $\alpha 6$  subunits assemble preferentially with the  $\delta$  subunit (Jones et al., 1997; Peng et al., 2002). The majority of mammalian brain GABA<sub>A</sub> receptors are probably  $\alpha\beta\gamma 2$  combinations. The subunit ratio is probably  $2\alpha/2\beta/1\gamma$  (Ernst et al., 2003). Some receptors also contain different  $\alpha$  and  $\beta$  subunits, e.g.,  $\alpha 1\alpha 2\beta 2\gamma 2$  (Benke et al., 2004). According to Benke et al., 2004, who analysed whole mouse brain samples, the  $\alpha 1\alpha 1\beta\gamma 2$  combination is the most abundant GABA<sub>A</sub> receptor subtype in the brain (61% of total). Other combinations were found in smaller quantities:  $\alpha 1\alpha 2\beta\gamma 2$  (13%),  $\alpha 1\alpha 3\beta\gamma 2$  (15%),  $\alpha 2\alpha 2\beta\gamma 2$  (12%),  $\alpha 2\alpha 3\beta\gamma 2$  (2%) and  $\alpha 3\alpha 3\beta\gamma 2$  (4%). Within the  $\alpha 1$ -containing receptor population, most receptors are

$\alpha 1\alpha 1\beta\gamma 2$ , whereas in the  $\alpha 2$ - and  $\alpha 3$ -containing receptor populations, receptors with two different  $\alpha$  subunit types predominate (Benke et al., 2004). Of course, these percentages are from homogenized brain; within particular cell types, some of these rare subtypes will be the most important receptor subtype. Other receptor subtypes relevant for the basal ganglia are *predicted* from subunit expression patterns as  $\alpha 4\beta\delta$  (or possibly  $\alpha 4\beta$  Bencsits et al., 1999) in the striatum and  $\alpha 1\beta 2\gamma 1$  in the globus pallidus.

## Synaptic GABA<sub>A</sub> receptors: $\alpha\beta\gamma$ subunit combinations and anchoring role of the $\gamma 2$ subunit and gephyrin

Placing GABA<sub>A</sub> receptors at synapses requires specific proteins that interact directly or indirectly with the  $\gamma$  subunits. For example, targeting some GABA<sub>A</sub> receptor subtypes to GABAergic terminals involves the widely expressed microtubule-binding protein gephyrin (Ramming et al., 2000). The best studied brain area for this has been the hippocampus, but splice forms of gephyrin are found throughout the basal ganglia (Ramming et al., 2000) and so the principles of GABA<sub>A</sub> receptor targeting would be expected to be similar there. In hippocampal neurons *in vitro* and *in vivo*, gephyrin either helps convey some GABA<sub>A</sub> receptor subtypes to the synapse or anchors them there—this requires the  $\gamma 2$  subunit (Kneussel et al., 1999; Brunig et al., 2002). Without the  $\gamma 2$  subunit, no GABA<sub>A</sub> receptors are found in synapses in the developing or adult hippocampus (Gunther et al., 1995; Essrich et al., 1998; Schweizer et al., 2003), and without gephyrin, much reduced numbers of some synaptic GABA<sub>A</sub> receptor subtypes, especially  $\alpha 2$ -containing, are found; some receptor clusters, especially those containing the  $\alpha 1$  subunit, persist in hippocampal gephyrin knockout neurons (Levi et al., 2004). Other  $\gamma$  subunits can replace synaptic targeting function of  $\gamma 2$ ; in  $\gamma 2$  knockout mice, GABA<sub>A</sub> receptors can be restored to hippocampal synapses by expressing the  $\gamma 3$  subunit by transgenic rescue (Baer et al., 1999; Luscher and Keller, 2004). Some conserved sequence identity in the large TM3-TM4 intracellular loops of the  $\gamma$  subunits may indicate binding sites for parts of the synapse-anchoring mechanism. Distributed cysteine residues are conserved in the  $\gamma$  subunit large intracellular loops, but are absent from the  $\alpha$ ,  $\beta$  and  $\delta$  subunits. Palmitoylation of these cysteine residues via a thioester bond plays some role in targeting  $\gamma$  subunit-containing receptors to the synapse (Luscher and Keller, 2004); in cultured hippocampal neurons, cysteine-alanine substitutions in the  $\gamma 2$  subunit loop region interfere with expression and clustering of receptors (Rathenberg et al., 2004). A surprising finding is that the TM4 region of the  $\gamma 2$  subunit is also involved in synaptic targeting, possibly by interacting with lipid rafts occurring in the synapse or by other membrane proteins (Alldred et al., 2005). In transfected hippocampal cultures, analyses of chimeric  $\gamma 2/\alpha 2$  subunit constructs showed that  $\gamma 2$  TM4 is necessary and sufficient for postsynaptic clustering of GABA<sub>A</sub> receptors, whereas the cytoplasmic  $\gamma 2$  subunit domains are dispensable (Alldred et al., 2005). In contrast, both the TM3-TM4 loop and the TM4 domain of the  $\gamma 2$  subunit contribute to efficient recruitment of gephyrin to postsynaptic receptor clusters and are essential for restoration of miniature inhibitory postsynaptic currents (IPSCs) (Alldred et al., 2005). Thus the  $\gamma 2$  subunit TM3-TM4 cytoplasmic loop might be needed for inserting receptors into the plasma membrane but is dispensable for delivery of receptors to subsynaptic dendritic sites (Alldred et al., 2005). Gephyrin does not bind the  $\gamma 2$  receptor subunit directly. The identity of the missing link(s) between gephyrin and GABA<sub>A</sub> receptor subunits is unknown. As mentioned earlier, the targeting of  $\gamma 2$ -containing receptors to hippocampal synapses must depend on both the  $\alpha$  subunit and the  $\gamma 2$  subunit. According to some investigators  $\alpha 5\beta\gamma 2$  receptors seem largely extrasynaptic and non-colocalized with gephyrin (Crestani et al., 2002) and when  $\alpha 6\beta\gamma 2$  receptors (normally only found in cerebellar granule cells) are ectopically expressed in pyramidal cells these receptors remain extrasynaptic (Wisden et al., 2002). So it is not simply that a  $\gamma 2$  subunit (or even gephyrin) guarantees a stable synaptic placement of the

GABA<sub>A</sub> receptor. In addition to gephyrin other clustering proteins must contribute to the synaptic localization of selected GABA<sub>A</sub> receptor subtypes (Kneussel et al., 2001).

### GABA<sub>A</sub> receptor occupancy at synapses is dynamic

It is important to keep in mind that GABA<sub>A</sub> receptor expression on the surface of neurons is dynamic; receptors rapidly recycle and leave from or insert into the synapse by rapid lateral diffusion and/or endo/exocytosis; a static crystalline scaffold of GABA<sub>A</sub> receptors anchored at the synapse would seem to be the wrong view (Kittler and Moss, 2003; Thomas et al., 2005); GABA<sub>A</sub> receptors diffuse into a synaptic zone and are transiently “captured” by the anchoring complex. However, for some inhibitory hippocampal synapses, a direct relationship exists between the number of synaptic GABA<sub>A</sub> receptors and the strength of the synapse, but it is not clear what mechanisms maintain fixed numbers of GABA<sub>A</sub> receptors long-term at specific synapses (reviewed in Nusser, 1999). As for glutamate receptors at excitatory synapses, neurons probably recycle GABA<sub>A</sub> receptors as a strategy for setting their degree of excitability (Kittler and Moss, 2003). GABA<sub>A</sub> receptors constitutively internalize by clathrin-dependent endocytosis; this requires interactions between the  $\beta$  and  $\gamma 2$  subunits and the AP2 adaptin complex (Kittler and Moss, 2003).

### Extrasynaptic GABA<sub>A</sub> receptors: $\alpha 4\beta\delta$ subtype

Besides mediating precisely timed synaptic point to point inhibition (phasic inhibition) via  $\gamma 2$  subunit-containing receptors, GABA<sub>A</sub> receptors can also convey less time-locked signals. Low GABA concentrations in the extracellular space, resulting from GABA diffusing from the synapse, can tonically activate extrasynaptic GABA<sub>A</sub> receptors (Fig. 3) (Brickley et al., 2001; Farrant and Nusser, 2005; Staley and Scharfmann, 2005). This “tonic inhibition” is temporally uncoupled from the fast synaptic events, causing a continually present background inhibitory conductance. Such conductances alter the input resistance of the cell and thus influence synaptic efficacy and integration; tonic extrasynaptic conductances, by increasing the electrical leakiness of the dendritic membrane, substantially and indiscriminately diminish the size of excitatory signals in dendrites (reviewed in Farrant and Nusser, 2005; Staley and Scharfmann, 2005).

Receptors with the  $\delta$  subunit,  $\alpha 4\beta\delta$  in forebrain and  $\alpha 6\beta\delta$  in cerebellar granule cells, are extrasynaptic;  $\delta$  subunits are perisynaptic (annular), localized around the edge of synapses in hippocampal dentate granule cells and totally extrasynaptic on cerebellar granule cells (Nusser et al., 1998; Wei et al., 2003). In all regions so far tested (cerebellar granule cells, hippocampal dentate granule cells, thalamic relay nuclei),  $\delta$  subunits contribute to GABA<sub>A</sub> receptors that provide an extrasynaptic tonic conductance (Brickley et al., 2001; Stell et al., 2003; Cope et al., 2005) For GABA<sub>A</sub> receptors containing  $\alpha 4\beta\delta$  subunits in the basal ganglia, for example in the striatum, it is predicted that the receptors are extrasynaptic and that their key properties are high affinity for neurotransmitter and limited desensitization, enabling them to contribute to tonic background conductances (see above) (Brickley et al., 2001; Semyanov et al., 2004).

### GABA<sub>A</sub> receptors: how subunit combinations affect synaptic and extrasynaptic transmission

Many factors will influence the type of IPSCs mediated by GABA<sub>A</sub> receptors: the number of GABA<sub>A</sub> receptors at the synapse; the subunit composition of the receptors which influences the kinetics; the phosphorylation state of the receptor; a differential modulation of synaptic and non-synaptic receptors; the Cl<sup>-</sup> reversal potential; the GABA transient in the synaptic cleft and regulation by neuromodulators (Mody and Pearce, 2004).

A typical synaptic pulse of GABA is often cited as 0.3-1.0 mM lasting less than 1 ms (Mody and Pearce, 2004). Under these conditions, all synaptic GABA<sub>A</sub> receptors will be saturated and give maximal responses. Nevertheless, receptor subunit composition affects the single channel conductance, how fast the receptors gate, how fast they switch off (deactivate and desensitize) and how they respond to allosteric modulators. GABA also diffuses out of the synaptic cleft, where  $\mu\text{M}$  GABA concentrations are typically present (Nusser and Farrant, 2005); at these concentrations the GABA sensitivity of the receptor is critical. The sensitivity of  $\alpha 1\beta 3$ - and  $\alpha 1\beta 3\delta$ -containing receptors is significantly higher (mean  $\text{EC}_{50}$  of approx. 2 and 3.5  $\mu\text{M}$ , respectively) than that of  $\alpha 1\beta 3\gamma 2$ -containing receptors (mean  $\text{EC}_{50}$  of approx. 13  $\mu\text{M}$ ) (Fisher and Macdonald, 1997). The single channel conductance of recombinant  $\alpha\beta\gamma 2$  or  $\alpha\beta\delta$  receptors lies in the range of 25-30 pS. The single channel conductance of  $\alpha\beta$ -heterodimeric channels is 11-15 pS (Fisher and Macdonald, 1997).

The transient kinetic properties of GABA<sub>A</sub> receptors depend on the subunit composition. The time course of the GABA<sub>A</sub> receptor current is governed by three different kinetic processes: activation, desensitization and deactivation. During activation the current shows a rapid rise to the maximum. During this time the agonist binds to the receptor and the channel opens. Desensitization describes the unresponsiveness of the receptor and current decline in the continued presence of agonist. Deactivation describes the current decline after removal of the agonist. Current activation for recombinant  $\alpha 1\beta 3$  and  $\alpha 1\beta 3\delta$  receptors is slower than for  $\alpha 1\beta 3\gamma 2$  receptors, with mean 10-90% rise time varying from 1.7 to 2.4 ms for  $\alpha 1\beta 3$  and  $\alpha 1\beta 3\delta$  receptors and only 0.5 ms for  $\alpha 1\beta 3\gamma 2$  receptors (Haas and Macdonald, 1999). The  $\alpha$  subunit also influences the activation rate. Recombinant  $\alpha 2\beta 1\gamma 2$  receptors have a more rapid activation (10-90% rise time of 0.5 ms) than  $\alpha 1\beta 1\gamma 2$  receptors (10-90% rise time of 1 ms) (Lavoie et al., 1997). Desensitization is also influenced by the subunit composition. Currents of recombinant  $\alpha 1\beta 3$  and  $\alpha 1\beta 3\gamma 2$  receptors desensitize quicker and more completely than currents of  $\alpha 1\beta 3\delta$  receptors (Haas and Macdonald, 1999). Thus the  $\delta$  subunit reduces speed and extent of receptor desensitization. As receptors with the  $\delta$  subunit are primarily extrasynaptically and perisynaptically located (Nusser et al., 1998; Wei et al., 2003), their limited desensitization and high sensitivity to GABA might be important for their roles in tonic background conductance (see Section "Extrasynaptic GABA<sub>A</sub> receptors:  $\alpha 4\beta\delta$  subtype", above).  $\alpha 1\beta 3\gamma 2$  currents deactivate more slowly than  $\alpha 1\beta 3$  or  $\alpha 1\beta 3\delta$  currents, mainly due to a significantly longer slow decay component (Haas and Macdonald, 1999). Again also the  $\alpha$  subunit composition influences the kinetics. Deactivation of  $\alpha 2\beta 1\gamma 2$  containing receptors is six to seven times slower than deactivation of  $\alpha 1\beta 1\gamma 2$  receptors (Lavoie et al., 1997).

## GABA<sub>A</sub> receptor agonists, antagonists and allosteric modulators

GABA<sub>A</sub> receptors display a rich pharmacology (Korpi et al., 2002a; Sieghart and Sperk, 2002; Rudolph and Moehler, 2006; Whiting, 2006). Generic GABA<sub>A</sub> receptors are selectively activated by the GABA agonist muscimol and blocked competitively by the GABA antagonists bicuculline and SR95531 (receptors assembled with  $\rho$  subunits are bicuculline- and barbiturate-insensitive, having their own unique pharmacology). Picrotoxin blocks GABA<sub>A</sub> receptors non-competitively, probably by binding to a site in the channel (Korpi et al., 2002a). Many drugs bind at sites on the GABA<sub>A</sub> receptor distinct from the GABA-binding site; these drugs change the shape of the receptor oligomer so that the efficacy of GABA at opening the channel is either increased (positive allosteric agonists, e.g., diazepam) or decreased (negative allosteric agonists, e.g., the  $\beta$ -carboline, DMCM). A few allosteric modulators occur naturally in the brain (e.g.,  $\text{Zn}^{2+}$ , neurosteroids). Generally, positive allosteric agonists are used widely in medicine (e.g., for the induction and maintenance of general anaesthesia or to treat anxiety disorders, states of agitation, epilepsy or sleep disorders) and there is scope to further develop these drugs to produce receptor



subtype-selective drugs with fewer side-effects (Whiting, 2006; Rudolph and Moehler, 2006); however, negative allosteric agonists also have potential clinical applications; for example, the drug L-655 708 works selectively at  $\alpha 5\beta\gamma 2$  receptors (a subtype mainly expressed in the hippocampus) and by decreasing GABA's action there it acts as a cognition enhancer (Rudolph and Moehler, 2006). A feature of all allosteric modulators is that they usually only work when GABA is at submaximal activating concentrations (below 1 mM) and they do not work in the absence of GABA (with the exception of some intravenous anaesthetics). Nevertheless, some modulators (e.g., benzodiazepines) also strongly influence the deactivation rate of the receptors even at peak synaptic GABA concentrations and this may be how some of their *in vivo* effects originate (Mellor and Randall, 1997). In the following sections, we briefly consider the drugs that could act on GABA<sub>A</sub> receptor subunit combinations relevant for the basal ganglia (e.g.,  $\alpha 1\beta 2\gamma 2$ ,  $\alpha 2\beta 2/3\gamma 2$ ,  $\alpha 4\beta\gamma 2$ ,  $\alpha 4\beta 6$ ) (see Section "Expression of GABA<sub>A</sub> receptor subunit genes in the basal ganglia" below).

### GABA<sub>A</sub> receptors: allosteric modulation by benzodiazepines and related ligands

The main effects of benzodiazepines are sedation, anxiolysis, suppression of seizures and muscle relaxation. These drugs require  $\alpha\beta\gamma 2$ -type receptors (e.g.,  $\alpha 1\beta 2\gamma 2$  or  $\alpha 2\beta 2\gamma 2$  or  $\alpha 1\beta 3\gamma 2$ ) with the drug-binding site located between the  $\alpha$  and  $\gamma 2$  subunits (Ernst et al., 2003). Note  $\alpha 4\beta\gamma 2$ -type receptors, which could potentially form in some nuclei of the basal ganglia, are insensitive to most BZ drugs, as are any receptors that contain the  $\delta$  subunit. The substances that act at the benzodiazepine-binding site include the classical benzodiazepines like diazepam or flunitrazepam as well as chemically different substances like the imidazopyridine zolpidem (relatively selective for  $\alpha 1\beta\gamma 2$ -type receptors). Depending on the ligand the benzodiazepine site can mediate different effects. Benzodiazepine antagonists like flumazenil (Ro 15-1788) inhibit the effects of both agonists (positive allosteric modulators) and inverse agonists (negative allosteric modulators). In clinics, flumazenil is used in cases of benzodiazepine intoxication.

The most abundant receptor subtype in the brain,  $\alpha 1\beta 2\gamma 2$  or  $\alpha 1\beta 3\gamma 2$ , corresponds to the pharmacologically defined BZ1 site with high affinity for flumazenil (Ro 15-1788), Ro 15-4513 and flunitrazepam and selective affinity for ligands like zolpidem (Niddam et al., 1987; Pritchett et al., 1989). Receptor subtypes containing the  $\alpha 2$  or  $\alpha 3$  subunit along with  $\beta$  and  $\gamma 2$  correspond to the BZ2 site with high affinity for flumazenil, Ro 15-4513 and flunitrazepam but lower affinity to zolpidem (Pritchett et al., 1989; Hadingham et al., 1993) (see also the Section "Autoradiography of GABA<sub>A</sub> receptors"). The type of  $\beta$  subunit has no effect on benzodiazepine pharmacology.

The BZ site is situated at the interface between the  $\alpha$  and the  $\gamma$  subunit (see Section "GABA<sub>A</sub> receptor structure") (Ernst et al., 2003; Ogris et al., 2004). In the  $\alpha 1$ ,  $\alpha 2$ ,  $\alpha 3$  and  $\alpha 5$  subunits a mutation from histidine to arginine at position 101 abolishes binding of classic agonists like diazepam (Wieland et al., 1992; Korpi et al., 2002a). The diazepam-insensitive  $\alpha 4$  (or  $\alpha 6$ ) subunits naturally contain an arginine residue at the homologous position and so  $\alpha 4\beta\gamma 2$  or  $\alpha 6\beta\gamma 2$  receptors are insensitive to most BZ ligands (Luddens et al., 1990; Wisden et al., 1991; Korpi et al., 2002a). In the  $\gamma 2$  subunit, a replacement of phenylalanine by isoleucine at position 77 abolishes binding of zolpidem, DMCM and flumazenil whereas flunitrazepam still shows high-affinity binding (Buhr et al., 1997; Wingrove et al., 1997; Cope et al., 2004; Ogris et al., 2004). Methionine at position 130 in the  $\gamma 2$  subunit is required for high-affinity binding of flunitrazepam but not flumazenil (Ro 15-1788) (Wingrove et al., 1997). The residues are distributed over the N-terminal domains of the  $\alpha$  and  $\gamma$  subunits. In the assembled receptor the residues that form the benzodiazepine-binding pocket are brought into close physical proximity by the so-called binding site "loops" (see Section "GABA<sub>A</sub> receptor structure"). It is not clear, however, whether each of the above-

mentioned amino acid residues really participates in the lining of the BZ-binding site or whether the inserted mutations have allosteric effects.

### **GABA<sub>A</sub> receptors: allosteric modulation by intravenous anaesthetics**

At clinically relevant concentrations, general anaesthetics modulate the activity of various ion channels (Krasowski and Harrison, 1999; Thompson and Wafford, 2001). Whereas volatile anaesthetics (e.g., halothane, enflurane or isoflurane) are positive modulators of recombinant GABA<sub>A</sub> receptors, the main targets of these drugs in vivo are probably two pore domain (K2P) potassium channels (Franks and Honore, 2004). The intravenous anaesthetics (e.g., barbiturates, steroidal anaesthetics, propofol and etomidate) can modulate GABA<sub>A</sub> action at the receptor but can also activate the receptor directly in the absence of GABA at higher concentrations (Korpi et al., 2002a). Based on the analysis of knock-in mouse lines with propofol- and etomidate-insensitive  $\beta$  subunits (see below), propofol and etomidate exert nearly all of their anaesthetic actions entirely through GABA<sub>A</sub> receptors (Rudolph and Mohler, 2004).

The action of etomidate and propofol absolutely requires residues in TM2 and TM3 in the  $\beta$ 2 or  $\beta$ 3 subunits (Jurd et al., 2003). A mutation of asparagine to methionine at position 265 (N265 M) in the 2nd transmembrane domain of the  $\beta$ 3 subunit abolishes the modulatory and direct effects of etomidate and propofol in recombinant receptors (Jurd et al., 2003). A mutation of asparagine at the same position in the  $\beta$ 2 subunit also abolishes the action of etomidate on the GABA<sub>A</sub> receptor (Reynolds et al., 2003). In  $\beta$ 3(N265 M) mice propofol and etomidate do not suppress noxious-evoked movements and show a strongly decreased duration of the loss of righting reflex, two different endpoints of anaesthesia. These results suggest that propofol and etomidate act mainly via the GABA<sub>A</sub> receptor and the  $\beta$ 3 subunit in particular to induce deep anaesthesia. The remaining effects of propofol and etomidate could be mediated by  $\beta$ 2 subunit-containing receptors. Studies on  $\beta$ 2(N265S) mice suggested that the  $\beta$ 2 subunit mediates the sedative effects of etomidate whereas the  $\beta$ 3 subunit is required for etomidate to induce a loss of consciousness (Reynolds et al., 2003). A highly interesting issue is the location in the brain where etomidate and propofol exert their anaesthetic effects. Is the modulation of GABA<sub>A</sub> receptors in specific nuclei required to induce anaesthesia or do these drugs produce global effects at many GABA<sub>A</sub> receptors in all brain circuits? In any case, as GABA<sub>A</sub> receptors with both  $\beta$ 2 and  $\beta$ 3 are found throughout the basal ganglia (see Section “Expression of GABA<sub>A</sub> receptor subunit genes in the basal ganglia”), the operation of these nuclei will be profoundly affected by propofol and etomidate.

### **GABA<sub>A</sub> receptors: allosteric modulation by neurosteroids**

Neuroactive steroids modulate GABA<sub>A</sub> receptor function in many brain regions (Belelli and Lambert, 2005; Farrant and Nusser, 2005). Naturally occurring steroid metabolites form locally in the brain: 5 $\alpha$ -reductase transforms progesterone to 5 $\alpha$ -DPH, which in turn is reduced by 3 $\alpha$ -hydroxysteroid oxidoreductase to allopregnanolone. Allopregnanolone potently activates GABA<sub>A</sub> receptors. No absolute specificity of neurosteroids for particular GABA<sub>A</sub> receptor subunit combinations exists. Many GABA<sub>A</sub> receptors are sensitive to the steroid tetrahydrodeoxycorticosterone (THDOC), but receptors with the  $\delta$  subunit are particularly sensitive — 30 nM THDOC enhances the peak currents of  $\alpha$ 1 $\beta$ 3 $\delta$  GABA<sub>A</sub> receptors (with 1  $\mu$ M GABA) by up to 800%; other receptor isoform currents, e.g., from  $\alpha$ 1 $\beta$ 3 $\gamma$ 2 are enhanced to a smaller degree (5-50%) (Mihalek et al., 1999; Wohlfarth et al., 2002; Stell et al., 2003). Thus endogenous allopregnanolone may act on extrasynaptic  $\alpha$  $\beta$  $\delta$  GABA<sub>A</sub> receptors to increase basal levels of inhibition. Mice without functional  $\delta$  subunits have decreased sensitivity to the sedative/hypnotic, anxiolytic and pro-absence effects of neuroactive steroids (Mihalek et al., 1999).

### GABA<sub>A</sub> receptors: allosteric modulation by Zn<sup>2+</sup>

Zn<sup>2+</sup> inhibits GABA<sub>A</sub> receptors (Hosie et al., 2003). In various brain regions, Zn<sup>2+</sup> is synaptically released together with other neurotransmitters, both GABA and glutamate (reviewed by Mathie et al., 2006). Hippocampal mossy fibres have actually been the main area where synaptic Zn<sup>2+</sup> actions have been investigated, but Zn<sup>2+</sup> is worth bearing in mind as a *potential* modulator of GABAergic function in the basal ganglia. Zn<sup>2+</sup> can reduce the amplitude, slow the rise time and accelerate the decay of mIPSCs. On recombinant GABA<sub>A</sub> receptors, Zn<sup>2+</sup> has an inhibitory potency 3400 times higher on αβ receptors than on αβγ2 receptors (reviewed in Hosie et al., 2003). Thus the γ2 subunit lowers the sensitivity of the GABA<sub>A</sub> receptor complex to Zn<sup>2+</sup>. Hosie and colleagues hypothesize that in addition to its role in promoting synaptic targeting and single channel conductance, the γ2 subunit evolved to retain the fidelity of GABAergic inhibition in the presence of Zn<sup>2+</sup> (Hosie et al., 2003). Nevertheless, the potency of Zn<sup>2+</sup> is also α subunit- and δ subunit-dependent.

### Extrasynaptic δ subunit-containing GABA<sub>A</sub> receptors: allosteric potentiation by ethanol

Blood alcohol levels of 1-3 mM can result from drinking half a glass of wine or less. Ethanol influences many channels, including the *N*-methyl-D-aspartate (NMDA) glutamate receptor (Hancher et al., 2005). But amongst GABA<sub>A</sub> receptor subunit combinations, low concentrations of ethanol (about 3 mM, a concentration six times lower than the legal blood-alcohol limit for driving in most States in the USA) specifically potentiate GABA responses of cloned α4βδ and α6βδ receptors expressed in *Xenopus* oocytes (Sundstrom-Poromaa et al., 2002; Wallner et al., 2003; Hancher et al., 2004, 2005). This effect is β subunit-dependent; β3 subunits provide maximal sensitivity to ethanol (Wallner et al., 2003). Thus a glass of wine might, via α4β3δ and α6β3δ receptors, enhance GABAergic tonic (extrasynaptic) inhibition in the striatum and cerebellum respectively (Hancher et al., 2005). On the other hand, the ethanol sensitivity of α6/δ KO mice is not different from wild-type mice (Korpi et al., 1999).

### New subtype-selective drugs for GABA<sub>A</sub> receptors

GABA<sub>A</sub> receptors have always been fertile ground for drug companies. Benzodiazepines, although for many years the main stay of clinical treatments for anxiety disorders, fell out of favour to selective serotonin reuptake inhibitors (SSRIs) due to side-effects like sedation, cognitive impairment and abuse liability. But SSRIs are too slow acting for some situations, requiring several weeks to work. Thus there is a medical need for fast-acting anxiolytics with few/no side-effects (Whiting, 2006). To dissociate the wanted anxiolytic effects from the unwanted side-effects of GABA<sub>A</sub> agonists, two different strategies were pursued: The development of partial agonists and the development of receptor subtype specific compounds. Despite promising preclinical assays, partial agonists (e.g., bretazenil) so far did not meet the expectations in clinical trials. One compound (ocinaplon) though was reported to show anxiolysis and strongly-reduced sedative side-effects in Phase II clinical trials (Whiting, 2006). Since different effects of benzodiazepines are mediated by different receptor subtypes, the second strategy has focussed on the development of compounds with selectivity for those subtypes proposed to mediate the anxiolytic effects of benzodiazepines, that is α2 and α3 subunit containing receptors (see Section "Function and physiological significance of GABA<sub>A</sub> receptor diversity for the basal ganglia", below). Some of these compounds (e.g., L-838417, TP003, SL 651498) showed a promising separation of anxiolytic effects and side-effects when tested in rodents and primates (McKernan et al., 2000; Griebel et al., 2001, 2003; Dias et al., 2005; Rowlett et al., 2005; Whiting, 2006). The usefulness of this second approach now has to be evaluated in clinical trials.

## Regulation of GABA<sub>A</sub> receptor function by neuromodulators: the role of kinases and phosphatases

Given that dopamine is a key neurotransmitter/neuromodulator in many parts of the basal ganglia and that dopamine receptors couple to G-protein-linked second messenger systems to alter kinase and phosphatase activity, it is appropriate to consider how GABA<sub>A</sub> receptor function is regulated by phosphorylation initiated by dopamine receptor activation (e.g., Chen et al., 2006). There has been one intriguing report that dopamine D5 receptors directly crosslink with GABA<sub>A</sub> receptors by using the TM3-TM4 loop of the  $\gamma$ 2 subunit (Liu et al., 2000); so far this finding has not been followed up, but it should not be dismissed too prematurely. But more conventionally, phosphorylation is the common way to regulate ion channels (Kittler and Moss, 2003). This is underlined by studies on, for example, PKC  $\epsilon$  knockout mice; these mice show increased anxiety and have impaired GABA<sub>A</sub> receptor function (Hodge et al., 1999). For the GABA<sub>A</sub> receptor, the intracellular loops of the  $\beta$  and  $\gamma$ 2 subunits in particular are phosphorylation targets. Studies of recombinant receptors have shown phosphorylation of these subunits by PKA, PKC, Src and PKB (Kittler and Moss, 2003; Wang et al., 2003). Depending on the subunit phosphorylation can have different functional effects, which might contribute to the diversity of GABA<sub>A</sub> receptor function. For example PKA mediated phosphorylation of the  $\beta$ 1 subunit (serine 409) leads to negative modulation of the receptor, whereas phosphorylation of the  $\beta$ 3 subunit (serine 408 and serine 409) enhances the activity of GABA<sub>A</sub> receptors (Kittler and Moss, 2003). Neuromodulators that influence GABA<sub>A</sub> receptor function via PKC include M1 muscarinic acetylcholine receptors, serotonin (5-HT) type 4 receptors and TrkB receptor stimulation via BDNF (Kittler and Moss, 2003; Jovanovic et al., 2004). Modulation of GABA<sub>A</sub> receptor function after dopamine D4 and D3 receptor activation depends on PKA (Wang et al., 2002; Chen et al., 2006). Protein kinase B (Akt) can phosphorylate the  $\beta$ 2 subunit at serine 410, which promotes rapid insertion of the GABA<sub>A</sub> receptor into the membrane, resulting in increased sIPSC amplitudes after stimulation with insulin (Wang et al., 2003).

## Function and physiological significance of GABA<sub>A</sub> receptor diversity for the basal ganglia

An important consequence of differences in subunit expression between cells or differential sub-cellular localization of subunits within a cell is that GABA<sub>A</sub> receptor kinetics might differ between different cells and different synapses (Thomson et al., 2000; Nyiri et al., 2001; Freund, 2003). In the hippocampus, for example, functionally distinct interneurons might signal via distinct GABA<sub>A</sub> receptor subtypes (Freund, 2003). A similar situation could occur in the basal ganglia.

Knockout mouse lines have been generated for many of the GABA<sub>A</sub> receptor subunit genes (reviewed by Vicini and Ortinski, 2004), but it would be hard to make observations specifically about altered basal ganglia function in these lines. In a beautiful series of papers, mice with specific mutations in the key H101 coding position affecting BZ sensitivity were generated in the  $\alpha$ 1,  $\alpha$ 2,  $\alpha$ 3 and  $\alpha$ 5 subunit genes and the behavioural effects of diazepam were tested (Rudolph and Mohler, 2004). These mice have normal GABA<sub>A</sub> receptors, but in  $\alpha$ 1H101R mice for example, only the  $\alpha$ 2 $\beta$  $\gamma$ 2,  $\alpha$ 3 $\beta$  $\gamma$ 2 and  $\alpha$ 5 $\beta$  $\gamma$ 2-type GABA<sub>A</sub> receptors are diazepam-sensitive. Thus by a process of subtraction, it can be deduced how different  $\alpha$ 1 $\beta$  $\gamma$ 2,  $\alpha$ 2 $\beta$  $\gamma$ 2,  $\alpha$ 3 $\beta$  $\gamma$ 2 and  $\alpha$ 5 $\beta$  $\gamma$ 2 subtypes contribute to the diverse in vivo pharmacological effects of diazepam and other ligands requiring the H101 site. Thus,  $\alpha$ 1H101R mice no longer become sleepy when given diazepam and so the  $\alpha$ 1 $\beta$  $\gamma$ 2 receptors are required for the sedative effects of diazepam (Rudolph and Mohler, 2004), whereas the  $\alpha$ 2 subunit mediates diazepam's anxiolytic effects (under the influence of diazepam

$\alpha 2\text{H}101\text{R}$  mice do not venture more into threatening areas, whereas their wild-type littermates do) (Rudolph and Mohler, 2004). A different set of studies using  $\alpha 3$  selective inverse agonists and agonists also showed a significant contribution of the  $\alpha 3$  subunit in anxiogenesis and anxiolysis (Atack et al., 2005; Dias et al., 2005). The muscle relaxant activity of diazepam is mediated by the  $\alpha 2$  and  $\alpha 3$  subunits, probably because these subunits are expressed in spinal motor neurons (Rudolph and Mohler, 2004). Nevertheless, because of the widespread expression of the  $\alpha 1$ ,  $\alpha 2$  and  $\alpha 3$  subunits, it is not easy to use results obtained from these mouse lines to make observations specifically about which  $\text{GABA}_A$  receptor subtypes respond to diazepam and influence basal ganglia function at the whole animal level; stereotactic injection of ligands into the various lines might be possible.

## Expression of $\text{GABA}_A$ receptor subunit genes in the basal ganglia

$\text{GABA}_A$  receptor expression in the basal ganglia has been mapped by ligand autoradiography (e.g., Niddam et al., 1987; Faull and Villiger, 1988; Olsen et al., 1990; Duncan et al., 1995; Waldvogel et al., 1999; Korpi et al., 2002a), in situ hybridization with gene-specific probes (e.g., Laurie et al., 1992a; Persohn et al., 1992; Petri et al., 2002; Wisden et al., 1992), single-cell polymerase chain reaction (PCR) (e.g., Criswell et al., 1997; Guyon et al., 1999; Okada et al., 2004) and immunocytochemistry with subunit-specific antibodies at the light and electron microscopic level (e.g., Fritschy and Mohler, 1995; Somogyi et al., 1996; Pirker et al., 2000; Fujiyama et al., 2000, 2002; Schwarzer et al., 2001).

### Autoradiography of $\text{GABA}_A$ receptors

Ligand autoradiography, although usually lacking cellular resolution, serves as a highly-useful indicator of which  $\alpha\beta\gamma 2$  subunit combination is present in a brain region (Korpi et al., 2002a) and is also a superbly quantitative technique (Korpi et al., 2002a). For example, the ligand [ $^3\text{H}$ ]flunitrazepam is incubated with a brain section in the absence or presence of the discriminating ligand CL 218 872. If the binding signal is reduced or even completely vanishes by co-incubation with CL 218 872 (which has high affinity for  $\alpha 1\beta\gamma 2$  receptors and so displaces [ $^3\text{H}$ ]flunitrazepam), then this is a “BZ1 region”. If CL 218 872 fails to displace [ $^3\text{H}$ ]flunitrazepam, then this is a “BZ2 -region” (reviewed in Niddam et al., 1987). Thus BZ1-type binding marks  $\alpha 1\beta\gamma 2$  receptors;  $^3\text{H}$ -zolpidem autoradiography on brain sections also selectively highlights  $\alpha 1\beta\gamma 2$  receptors directly (Duncan et al., 1995; Korpi et al., 2002a). BZ2-type binding marks  $\alpha 2$ ,  $\alpha 3$  and  $\alpha 5\beta\gamma 2$  type receptors (the  $\alpha 4\beta\gamma 2$  receptors are not picked up by this method, as they do not bind [ $^3\text{H}$ ]flunitrazepam — see Section “ $\text{GABA}_A$  receptors: allosteric modulation by benzodiazepines and related ligands”). The  $\alpha\beta\gamma$ -type receptors with  $\gamma 1$  or  $\gamma 3$  are not picked up by BZ1 and BZ2 screening, neither are  $\alpha 4\beta\delta$ -type receptors. However, many novel ligands are available these days, which could be used as autoradiographic probes.

Autoradiography with [ $^3\text{H}$ ]muscimol (high-affinity site), commonly assumed to mark all  $\text{GABA}_A$  receptors, selectively marks only  $\alpha 4\beta\delta$  and  $\alpha 6\beta\delta$  receptors; mouse brain sections with no  $\delta$  subunit no longer give detectable [ $^3\text{H}$ ]muscimol signals (Korpi et al., 2002b). Thus the [ $^3\text{H}$ ]muscimol autoradiographic signals detected in many basal ganglia areas such as the striatum (Olsen et al., 1990; Jones et al., 1997; Korpi et al., 2002b) will originate from  $\alpha 4\delta$  -containing receptors.

### In situ hybridization and immunocytochemistry of $\text{GABA}_A$ receptors

In situ hybridization is used to localize mRNA in brain regions or cell types. The radioactive version is a sensitive assay for which cell type expresses which gene; the use of digoxigenin-labelled probes is less sensitive but permits double labelling for multiple gene

expression. There is good agreement between different labs on the results with GABA<sub>A</sub> receptor gene expression, probably because hybridization of nucleic acids is reasonably standardized between labs. The disadvantage of in situ hybridization is that no information is obtained on protein localization on the cell, or even if the mRNA is translated. Thus immunocytochemistry with subunit-specific antibodies gives the ultimate biological information. However, antibodies can be problematic; Saper and Sawchenko (2003) point out that antibodies are biological agents, not standard chemical reagents: antibodies may bind to a wide variety of antigens other than the one that they were raised to recognize and there is no way to be sure that the pattern they stain really represents that antigen. If investigating localization in the rodent nervous system, a knockout mouse for the particular antigen is the best control of antibody specificity (Saper and Sawchenko, 2003; Aller et al., 2005). This has been done for some (e.g.,  $\alpha 1$ ,  $\alpha 3$ ,  $\alpha 6$  and  $\delta$ ) (Jones et al., 1997; Tretter et al., 2001; Yee et al., 2005; Kralic et al., 2006), but not all GABA<sub>A</sub> receptor antibodies used in published papers.

### Occurrence of $\alpha 1/\beta 2/\gamma 2$ receptors throughout the basal ganglia

The  $\alpha 1/\beta 2/\gamma 2$  GABA<sub>A</sub> receptor subtype is the most abundant subtype in the brain (Benke et al., 2004). Many cell types in the basal ganglia use the “standard” BZ1-type  $\alpha 1/\beta 2/\gamma 2$  receptor subtype: neurons in the caudate-putamen (striatum), substantia nigra pars reticulata; globus pallidus and subthalamic nucleus, all use this receptor (see Niddam et al., 1987; Wisden et al., 1989, 1992; Criswell et al., 1997; Chen et al., 2004). The subthalamic nucleus, substantia nigra pars reticulata, globus pallidus and ventral pallidum are classic BZ1 sites, having some of the highest densities of [<sup>3</sup>H]zolpidem binding (Niddam et al., 1987; Duncan et al., 1995).

### Mixed GABA<sub>A</sub> receptors in the striatum: synaptic $\alpha 1/\beta 2/\gamma 2$ , $\alpha 2/\beta 3/\gamma 2$ , $\alpha 3/\beta 2/\gamma 2$ and extrasynaptic $\alpha 4/\beta 3/\delta$

Consistent with the diversity of neuronal cell types in the striatum (Tepper and Bolam, 2004), a diverse mixture of GABA<sub>A</sub> receptor subtypes exists in this structure. By in situ hybridization, this region expresses moderately  $\alpha 1$ , strongly  $\alpha 2$ , moderately  $\alpha 3$ , strongly  $\alpha 4$  (about the same as  $\alpha 2$ ), moderately  $\beta 2$  (about the same as  $\alpha 1$ ), strongly  $\beta 3$  (about the same as  $\alpha 2$  and  $\alpha 4$ ), moderately  $\gamma 1$ ,  $\gamma 2$  and  $\gamma 3$  and moderately  $\delta$  mRNAs (Wisden et al., 1991, 1992; Herb et al., 1992). In the rat,  $\gamma 3$  mRNA is slightly more abundant in the caudate-putamen than  $\gamma 2$  and  $\gamma 1$  mRNAs (see Figs. 2 and 3 in Herb et al., 1992). The significance of receptors containing the  $\gamma 1$  and  $\gamma 3$  type receptors has not been investigated, but we think it would be rewarding to examine.

In the rat striatum, based on assembly rules from other brain regions, we might expect  $\alpha 1/\beta 2/\gamma 2$ ,  $\alpha 2/\beta 3/\gamma 2$ ,  $\alpha 3/\beta 2/\gamma 2$  (all synaptic, or  $\alpha 1\alpha X$  mixtures), and  $\alpha 4/\beta 3/\delta$  (or possibly  $\alpha 4/\beta 3$ ) receptors, distributed within and between different cell types, and sometimes co-expressed on the same cell type (Fujiyama et al., 2000). Just by the sheer abundance and rather uniform distribution in the striatum of the  $\alpha 2$  and  $\beta 3$  mRNAs, we predict that GABA<sub>A</sub> receptors containing  $\alpha 2$  and  $\beta 3$  will be on GABAergic projection neurons.

### Strong developmental switch in GABA<sub>A</sub> receptor subunit expression in the striatum from neonate to adult

There is much interest in identifying the role(s) GABA and its (generic) receptors may have in shaping the development of the postnatal nervous system (Ben-Ari et al., 2004). A marked switch in  $\alpha$  subunit gene expression takes place during rat striatal development: the  $\alpha 2$ , and  $\alpha 5$  mRNAs are present in the neonatal period at E19 to P6; but in the adult, the  $\alpha 2$  and  $\alpha 4$  mRNAs predominate (Laurie et al., 1992b). The  $\alpha 5$  subunit gene is strongly expressed in the neonatal period in the caudate; and then the gene switches off. Any

significance of this very clear subunit switch in GABA<sub>A</sub> receptor expression during striatal development has remained unstudied.

### Occurrence of $\alpha 1\beta 2\gamma 1$ or $\alpha 2\beta 2\gamma 1$ receptors in the rodent globus pallidus

The globus pallidus expresses a lot of  $\alpha 1$  mRNA, some  $\alpha 2$ , a lot of  $\beta 2$  mRNA, and some of both  $\gamma 1$  and some  $\gamma 2$ , with more  $\gamma 1$  than  $\gamma 2$  mRNA;  $\gamma 3$  mRNA is not present (Wisden et al., 1992). The subunits in the globus pallidus (examined with  $\alpha 1$ ,  $\beta 2/3$  and  $\gamma 2$  antibodies) are concentrated in GABAergic (symmetrical, type II) synapses as assessed by postembedding, immuno-electron-microscopy (Somogyi et al., 1996). The mIPSCs recorded in the rat globus pallidus are zolpidem-sensitive, fitting with the expected  $\alpha 1\beta 2\gamma 2$  type receptors (Chen et al., 2004). But the globus pallidus is one of the few brain areas that have elevated levels of the otherwise rarely expressed  $\gamma 1$  subunit, although its levels in the neighbouring bed nucleus, stria terminalis and medial preoptic nucleus are even higher (Pirker et al., 2000; Schwarzer et al., 2001; Herb et al., 1992; Laurie et al., 1992b; Wisden et al., 1992). The brain areas that express  $\gamma 1$  tend to also have  $\alpha 2$  mRNA (Wisden et al., 1992) and so  $\alpha 2\beta 2\gamma 1$  might be the combination. It is not known if the occurrence of  $\alpha 1$ ,  $\alpha 2$ ,  $\beta 2$ ,  $\gamma 1$  and  $\gamma 2$  produce subtypes of receptor on the same cell type or if the  $\gamma 1$  and  $\gamma 2$  are in different cell types in the globus pallidus. The function of receptors with the  $\gamma 1$  subunit has been relatively ignored by GABA<sub>A</sub> researchers, but one would expect that, for example,  $\alpha 1\beta 2\gamma 1$  receptors would be synaptically located, with a 25-30 pS single channel conductance, but with an unknown pharmacological profile.

### Strong developmental changes in GABA<sub>A</sub> receptor subunit expression in the developing globus pallidus

During postnatal development, the expression of  $\gamma 1$  mRNA in the globus pallidus is even higher (Laurie et al., 1992b). As for the striatum, a very marked switch in subunit gene expression takes place during rat globus pallidus development: the  $\alpha 2$ , ( $\alpha 3$ ),  $\beta 2$  and  $\gamma 1$  genes are expressed in the neonatal (E19-P6) globus pallidus, whereas the  $\alpha 1$ , ( $\alpha 2$ ),  $\beta 2$ ,  $\gamma 1$  and  $\gamma 2$  mRNAs are found in the adult structure (Laurie et al., 1992b).

### Substantia nigra reticulata

Substantia nigra neurons express mainly  $\alpha 1$ ,  $\beta 2$  and  $\gamma 2$  mRNA and protein (Wisden et al., 1992; Fujiyama et al., 2002); post-embedding immunogold labelling showed that these subunits are enriched in symmetrical (GABAergic) synapses (Fujiyama et al., 2002). The main receptor subtype in all cell types in the reticulata will thus be the "standard" BZ1-version ( $\alpha 1/\beta 2/3\gamma 2$ ) (see also Niddam et al., 1987; Duncan et al., 1995).

### Substantia nigra compacta

The dopaminergic compacta cells receive GABA from GABAergic interneurons in the pars reticulata and in addition, a direct GABAergic input from the striatum and the pallidum, although controversy exists about the involvement of postsynaptic GABA<sub>A</sub> and/or GABA<sub>B</sub> receptors in the striato-nigral and pallido-nigral paths (Misgeld, 2004). GABA<sub>A</sub> receptors could be on the cell soma and dendrites of the compacta cells; some GABA<sub>A</sub> receptors could be located on the compacta axon terminals far away in the striatum, where they might regulate locally release of dopamine. Compacta cells express a complex mix of GABA<sub>A</sub> receptor subunits, which may also vary with species: by in situ hybridization, rodent cells express significant  $\alpha 4$ , less  $\alpha 3$ , no  $\delta$ ,  $\beta 3$ , and possibly all three  $\gamma$  subunits (Wisden et al., 2002). Note this is one of the few brain areas where the  $\alpha 4$  subunit occurs without the  $\delta$  subunit, hippocampal pyramidal cells being the other example; thus in nigra compacta cells,  $\alpha 4$  either forms  $\alpha 4\beta$  complexes or  $\alpha 4\beta\gamma$  complexes; this is unknown. Single-cell PCR on rodent dopaminergic compacta cells gives contradictory results:  $\alpha 3$ ,  $\alpha 4$ ,  $\beta 2$ ,  $\beta 3$  and  $\gamma 3$  were

detected in one study (Guyon et al., 1999),  $\alpha 2$ ,  $\alpha 3$ ,  $\alpha 4$ ,  $\beta 1$ ,  $\beta 3$  and  $\gamma 2$  in another (Okada et al., 2004). Both studies agree on  $\alpha 3$  and  $\alpha 4$ , and that there is no  $\delta$  subunit mRNA, fitting with the in situ hybridization data. In contrast, immunocytochemical analysis showed immunoreactivity mainly for  $\alpha 3$ ,  $\gamma 3$  and  $\delta$  on potentially dopaminergic neurons (Schwarzer et al., 2001); but here the detection of the  $\delta$  immunore-activity is at odds with the RNA data. The relevance of the  $\alpha 3$  subunit in dopaminergic neurons is supported by electrophysiological analysis of  $\alpha 3$  KO animals. Whole-cell GABA currents were reduced to less than 50% after bath application of GABA to compacta neurons (Yee et al., 2005).

Species differences in expression are likely: an in situ hybridization study on human substantia nigra compacta found strong expression of  $\alpha 1$  subunit mRNA along with  $\beta 2$  and  $\gamma 2$  in about 25% of the compacta cells, suggesting an inhibitory input via the “standard”  $\alpha 1\beta 2\gamma 2$  receptor subtype in a subpopulation of dopaminergic neurons in humans (Petri et al., 2002).

## Acknowledgments

Research in our lab is supported by the Deutsche Forschungsgemeinschaft (Wi 1951/2-1) (Wulff and Wisden), the DFG Graduate College (GK 791) (Arslan), University of Heidelberg Young Investigator Award (Wulff) and Fonds der Chemischen Industrie (Wisden).

## References

- Allred MJ, Mulder-Rosi J, Lingenfelter SE, Chen G, Luscher B. Distinct gamma2 subunit domains mediate clustering and synaptic function of postsynaptic GABA<sub>A</sub> receptors and gephyrin. *J. Neurosci.* 2005; 25:594–603. [PubMed: 15659595]
- Aller MI, Veale EL, Linden AM, Sandu C, Schwaninger M, Evans LJ, Korpi ER, Mathie A, Wisden W, Brickley SG. Modifying the subunit composition of TASK channels alters the modulation of a leak conductance in cerebellar granule neurons. *J. Neurosci.* 2005; 25:11455–11467. [PubMed: 16339039]
- Atack JR, Hutson PH, Collinson N, Marshall G, Bentley G, Moyes C, Cook SM, Collins I, Wafford K, McKernan RM, Dawson GR. Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA<sub>A</sub> receptors. *Br. J. Pharmacol.* 2005; 144:357–366. [PubMed: 15655523]
- Baer K, Essrich C, Benson JA, Benke D, Bluethmann H, Fritschy JM, Luscher B. Postsynaptic clustering of GABA<sub>A</sub> receptors by the  $\gamma 3$  subunit in vivo. *Proc. Natl. Acad. Sci. USA.* 1999; 96:12860–12865. [PubMed: 10536013]
- Baumann SW, Baur R, Sigel E. Forced subunit assembly in alpha1beta2gamma2 GABA<sub>A</sub> receptors. Insight into the absolute arrangement. *J. Biol. Chem.* 2002; 277:46020–46025. [PubMed: 12324466]
- Baumann SW, Baur R, Sigel E. Individual properties of the two functional agonist sites in GABA<sub>A</sub> receptors. *J. Neurosci.* 2003; 23:11158–11166. [PubMed: 14657175]
- Bellesi D, Lambert JJ. Neurosteroids: endogenous regulators of the GABA(A) receptor. *Nat. Rev. Neurosci.* 2005; 6:565–755. [PubMed: 15959466]
- Ben-Ari Y, Khalilov I, Represa A, Gozlan H. Interneurons set the tune of developing networks. *Trends Neurosci.* 2004; 27:422–427. [PubMed: 15219742]
- Bencsits E, Ebert V, Tretter V, Sieghart W. A significant part of native gamma-aminobutyric AcidA receptors containing alpha4 subunits do not contain gamma or delta subunits. *J. Biol. Chem.* 1999; 274:19613–19616. [PubMed: 10391897]
- Benke D, Fakitsas P, Roggenmoser C, Michel C, Rudolph U, Mohler H. Analysis of the presence and abundance of GABA<sub>A</sub> receptors containing two different types of alpha subunits in murine brain using point-mutated alpha subunits. *J. Biol. Chem.* 2004; 279:43654–43660. [PubMed: 15304513]
- Bonnert TP, McKernan RM, Farrar S, le Bourdelles B, Heavens RP, Smith DW, Hewson L, Rigby MR, Sirinathsinghji DJ, Brown N, Wafford KA, Whiting PJ. Theta, a novel gamma-aminobutyric



- acid type A receptor subunit. *Proc. Natl. Acad. Sci. USA*. 1999; 96:9891–9896. [PubMed: 10449790]
- Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van Der Oost J, Smit AB, Sixma TK. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. *Nature*. 2001; 411:269–276. [PubMed: 11357122]
- Brickley SG, Revilla V, Cull-Candy SG, Wisden W, Farrant M. Adaptive regulation of neuronal excitability by a voltage-independent potassium conductance. *Nature*. 2001; 409:88–92. [PubMed: 11343119]
- Brunig I, Suter A, Knuesel I, Luscher B, Fritschy JM. GABAergic terminals are required for postsynaptic clustering of dystrophin but not of GABA(A) receptors and gephyrin. *J. Neurosci*. 2002; 22:4805–4813. [PubMed: 12077177]
- Buhr A, Baur R, Sigel E. Subtle changes in residue 77 of the gamma subunit of alpha1beta2gamma2 GABA<sub>A</sub> receptors drastically alter the affinity for ligands of the benzodiazepine binding site. *J. Biol. Chem*. 1997; 272:11799–11804. [PubMed: 9115236]
- Chen G, Kittler JT, Moss SJ, Yan Z. Dopamine D3 receptors regulate GABA<sub>A</sub> receptor function through a phospho-dependent endocytosis mechanism in nucleus accumbens. *J. Neurosci*. 2006; 26:2513–2521. [PubMed: 16510729]
- Chen L, Savio Chan C, Yung WH. Electrophysiological and behavioral effects of zolpidem in rat globus pallidus. *Exp. Neurol*. 2004; 186:212–220. [PubMed: 15026257]
- Cope DW, Hughes SW, Crunelli V. GABA<sub>A</sub> receptor-mediated tonic inhibition in thalamic neurons. *J. Neurosci*. 2005; 25:11553–11563. [PubMed: 16354913]
- Cope DW, Wulff P, Oberto A, Aller MI, Capogna M, Ferraguti F, Halbsguth C, Hoeger H, Jolin HE, Jones A, McKenzie AN, Ogris W, Poeltl A, Sinkkonen ST, Vekovischeva OY, Korpi ER, Sieghart W, Sigel E, Somogyi P, Wisden W. Abolition of zolpidem sensitivity in mice with a point mutation in the GABA<sub>A</sub> receptor gamma2 subunit. *Neuropharmacology*. 2004; 47:17–34. [PubMed: 15165831]
- Crestani F, Keist R, Fritschy JM, Benke D, Vogt K, Prut L, Bluthmann H, Mohler H, Rudolph U. Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. *Proc. Natl. Acad. Sci. USA*. 2002; 99:8980–8985. [PubMed: 12084936]
- Criswell HE, McCown TJ, Moy SS, Oxford GS, Mueller RA, Morrow AL, Breese GR. Action of zolpidem on responses to GABA in relation to mRNAs for GABA(A) receptor alpha subunits within single cells: evidence for multiple functional GABA(A) isoreceptors on individual neurons. *Neuropharmacology*. 1997; 36:1641–1652. [PubMed: 9517435]
- Cromer BA, Morton CJ, Parker MW. Anxiety over GABA<sub>A</sub> receptor structure relieved by AChBP. *Trends Biochem. Sci*. 2002; 27:280–287. [PubMed: 12069787]
- Davies PA, Hanna MC, Hales TG, Kirkness EF. Insensitivity to anaesthetic agents conferred by a class of GABA(A) receptor subunit. *Nature*. 1997; 385:820–823. [PubMed: 9039914]
- Dias R, Sheppard WF, Fradley RL, Garrett EM, Stanley JL, Tye SJ, Goodacre S, Lincoln RJ, Cook SM, Conley R, Hallett D, Humphries AC, Thompson SA, Wafford KA, Street LJ, Castro JL, Whiting PJ, Rosahl TW, Atack JR, McKernan RM, Dawson GR, Reynolds DS. Evidence for a significant role of alpha 3-containing GABA<sub>A</sub> receptors in mediating the anxiolytic effects of benzodiazepines. *J. Neurosci*. 2005; 25:10682–10688. [PubMed: 16291941]
- Duncan GE, Breese GR, Criswell HE, McCown TJ, Herbert JS, Devaud LL, Morrow AL. Distribution of [<sup>3</sup>H]zolpidem binding sites in relation to messenger RNA encoding the alpha 1, beta 2 and gamma 2 subunits of GABA<sub>A</sub> receptors in rat brain. *Neuroscience*. 1995; 64:1113–1128. [PubMed: 7753379]
- Ernst M, Brauchart D, Boresch S, Sieghart W. Comparative modeling of GABA(A) receptors: limits, insights, future developments. *Neuroscience*. 2003; 119:933–943. [PubMed: 12831854]
- Essrich C, Lorez M, Benson JA, Fritschy JM, Luscher B. Postsynaptic clustering of major GABA<sub>A</sub> receptor subtypes requires the gamma 2 subunit and gephyrin. *Nat. Neurosci*. 1998; 1:563–571. [PubMed: 10196563]
- Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. *Nat. Rev. Neurosci*. 2005; 6:215–229. [PubMed: 15738957]

- Faull RL, Villiger JW. Multiple benzodiazepine receptors in the human basal ganglia: a detailed pharmacological and anatomical study. *Neuroscience*. 1988; 24:433–451. [PubMed: 2834664]
- Fisher JL, Macdonald RL. Single channel properties of recombinant GABA<sub>A</sub> receptors containing gamma 2 or delta subtypes expressed with alpha 1 and beta 3 subtypes in mouse L929 cells. *J. Physiol.* 1997; 505:283–297. [PubMed: 9423172]
- Fiumelli H, Cancedda L, Poo MM. Modulation of GABAergic transmission by activity via postsynaptic Ca<sup>2+</sup>-dependent regulation of KCC2 function. *Neuron*. 2005; 48:773–786. [PubMed: 16337915]
- Franks NP, Honore E. The TREK K2P channels and their role in general anaesthesia and neuroprotection. *Trends Pharmacol. Sci.* 2004; 25:601–608. [PubMed: 15491783]
- Freund TF. Interneuron Diversity series: rhythm and mood in perisomatic inhibition. *Trends Neurosci.* 2003; 26:489–495. [PubMed: 12948660]
- Fritschy JM, Mohler H. GABA<sub>A</sub>-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. *J. Comp. Neurol.* 1995; 359:154–194. [PubMed: 8557845]
- Fujiyama F, Fritschy JM, Stephenson FA, Bolam JP. Synaptic localization of GABA<sub>A</sub> receptor subunits in the striatum of the rat. *J. Comp. Neurol.* 2000; 416:158–172. [PubMed: 10581463]
- Fujiyama F, Stephenson FA, Bolam JP. Synaptic localization of GABA<sub>A</sub> receptor subunits in the substantia nigra of the rat: effects of quinolinic acid lesions of the striatum. *Eur. J. Neurosci.* 2002; 15:1961–1975. [PubMed: 12099902]
- Galzi JL, Devillers-Thiery A, Hussy N, Bertrand S, Changeux JP, Bertrand D. Mutations in the channel domain of a neuronal nicotinic receptor convert ion selectivity from cationic to anionic. *Nature*. 1992; 359:500–505. [PubMed: 1383829]
- Grenningloh G, Rienitz A, Schmitt B, Methfessel C, Zensen M, Beyreuther K, Gundelfinger ED, Betz H. The strychnine-binding subunit of the glycine receptor shows homology with nicotinic acetylcholine receptors. *Nature*. 1987; 328:215–220. [PubMed: 3037383]
- Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Decobert M, Francon D, Avenet P, Depoortere H, Tan S, Oblin A, Schoemaker H, Evanno Y, Sevrin M, George P, Scatton B. SL651498: an anxiolytic compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors. *J. Pharmacol. Exp. Ther.* 2001; 298:753–768. [PubMed: 11454940]
- Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Depoortere H, Francon D, Avenet P, Schoemaker H, Evanno Y, Sevrin M, George P, Scatton B. SL651498, a GABA<sub>A</sub> receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms. *CNS Drug Rev.* 2003; 9:3–20. [PubMed: 12595909]
- Gulasci A, Lee CR, Sik A, Viitanen T, Kaila K, Tepper JM, Freund TF. Cell-type specific differences in chloride-regulatory mechanisms and GABA<sub>A</sub> receptor-mediated inhibition in rat substantia nigra. *J. Neurosci.* 2003; 23:8237–8246. [PubMed: 12967985]
- Gunther U, Benson J, Benke D, Fritschy JM, Reyes G, Knoflach F, Crestani F, Aguzzi A, Arigoni M, Lang Y, Bluethmann H, Mohler H, Luscher B. Benzodiazepine-insensitive mice generated by targeted disruption of the gamma 2 subunit gene of gamma-aminobutyric acid type A receptors. *Proc. Natl. Acad. Sci. USA.* 1995; 92:7749–7753. [PubMed: 7644489]
- Guyon A, Laurent S, Paupardin-Tritsch D, Rossier J, Eugene D. Incremental conductance levels of GABA<sub>A</sub> receptors in dopaminergic neurones of the rat substantia nigra pars compacta. *J. Physiol.* 1999; 516:719–737. [PubMed: 10200421]
- Haas KF, Macdonald RL. GABA<sub>A</sub> receptor subunit gamma2 and delta subtypes confer unique kinetic properties on recombinant GABA<sub>A</sub> receptor currents in mouse fibroblasts. *J. Physiol.* 1999; 514:27–45. [PubMed: 9831714]
- Hadingham KL, Wingrove P, Le Bourdelles B, Palmer KJ, Ragan CI, Whiting PJ. Cloning of cDNA sequences encoding human alpha 2 and alpha 3 gamma-aminobutyric acidA receptor subunits and characterization of the benzodiazepine pharmacology of recombinant alpha 1-, alpha 2-, alpha 3-, and alpha 5-containing human gamma-aminobutyric acidA receptors. *Mol. Pharmacol.* 1993; 43:970–975. [PubMed: 8391122]

- Hales TG, Dunlop JI, Deeb TZ, Carland JE, Kelley SP, Lambert JJ, Peters JA. Common determinants of single channel conductance within the large cytoplasmic loop of 5-HT<sub>3</sub> and alpha 4beta 2 nicotinic acetylcholine receptors. *J. Biol. Chem.* 2006 in press.
- Hanchar HJ, Dodson PD, Olsen RW, Otis TS, Wallner M. Alcohol-induced motor impairment caused by increased extrasynaptic GABA(A) receptor activity. *Nat. Neurosci.* 2005; 8:339–345. [PubMed: 15696164]
- Hanchar HJ, Wallner M, Olsen RW. Alcohol effects on  $\gamma$ -aminobutyric acid type A receptors: are extrasynaptic receptors the answer? *Life Sci.* 2004; 76:1–8. [PubMed: 15501475]
- Hedblom E, Kirkness EF. A novel class of GABA<sub>A</sub> receptor subunit in tissues of the reproductive system. *J. Biol. Chem.* 1997; 272:15346–15350. [PubMed: 9182563]
- Herb A, Wisden W, Luddens H, Puia G, Vicini S, Seeburg PH. The third gamma subunit of the gamma-aminobutyric acid type A receptor family. *Proc. Natl. Acad. Sci. USA.* 1992; 89:1433–1437. [PubMed: 1311098]
- Hodge CW, Mehmert KK, Kelley SP, McMahon T, Haywood A, Olive MF, Wang D, Sanchez-Perez AM, Messing RO. Supersensitivity to allosteric GABA(A) receptor modulators and alcohol in mice lacking PKCepsilon. *Nat. Neurosci.* 1999; 2:997–1002. [PubMed: 10526339]
- Hosie AM, Dunne EL, Harvey RJ, Smart TG. Zinc-mediated inhibition of GABA(A) receptors: discrete binding sites underlie subtype specificity. *Nat. Neurosci.* 2003; 6:362–369. [PubMed: 12640458]
- Jensen ML, Timmermann DB, Johansen TH, Schousboe A, Varming T, Ahring PK. The  $\beta$  subunit determines the ion selectivity of the GABA<sub>A</sub> receptor. *J. Biol. Chem.* 2002; 277:41438–41447. [PubMed: 12177063]
- Jones A, Korpi ER, McKernan RM, Pelz R, Nusser Z, Makela R, Mellor JR, Pollard S, Bahn S, Stephenson FA, Randall AD, Sieghart W, Somogyi P, Smith AJ, Wisden W. Ligand-gated ion channel subunit partnerships: GABA<sub>A</sub> receptor alpha6 subunit gene inactivation inhibits delta subunit expression. *J. Neurosci.* 1997; 17:1350–1362. [PubMed: 9006978]
- Jovanovic JN, Thomas P, Kittler JT, Smart TG, Moss SJ. Brain-derived neurotrophic factor modulates fast synaptic inhibition by regulating GABA(A) receptor phosphorylation, activity, and cell-surface stability. *J. Neurosci.* 2004; 24:522–530. [PubMed: 14724252]
- Jurd R, Arras M, Lambert S, Drexler B, Sieghart R, Crestani F, Zaugg M, Vogt KE, Ledermann B, Antkowiak B, Rudolph U. General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta3 subunit. *FASEB J.* 2003; 17:250–252. [PubMed: 12475885]
- Kaila K, Lamsa K, Smirnov S, Taira T, Voipio J. Long-lasting GABA-mediated depolarization evoked by high-frequency stimulation in pyramidal neurons of rat hippocampal slice is attributable to a network-driven, bicarbonate-dependent K<sup>+</sup> transient. *J. Neurosci.* 1997; 17:7662–7672. [PubMed: 9315888]
- Kash TL, Dizon MJ, Trudell JR, Harrison NL. Charged residues in the beta2 subunit involved in GABA<sub>A</sub> receptor activation. *J. Biol. Chem.* 2004; 279:4887–4893. [PubMed: 14610076]
- Kash TL, Jenkins A, Kelley JC, Trudell JR, Harrison NL. Coupling of agonist binding to channel gating in the GABA(A) receptor. *Nature.* 2003; 421:272–275. [PubMed: 12529644]
- Kittler JT, Moss SJ. Modulation of GABA<sub>A</sub> receptor activity by phosphorylation and receptor trafficking: implications for the efficacy of synaptic transmission. *Curr. Opin. Neurobiol.* 2003; 13:341–347. [PubMed: 12850219]
- Kneussel M, Brandstatter JH, Gasnier B, Feng G, Sanes JR, Betz H. Gephyrin-independent clustering of postsynaptic GABA(A) receptor subtypes. *Mol. Cell Neurosci.* 2001; 17:973–982. [PubMed: 11414787]
- Kneussel M, Brandstatter JH, Laube B, Stahl S, Muller U, Betz H. Loss of postsynaptic GABA(A) receptor clustering in gephyrin-deficient mice. *J. Neurosci.* 1999; 19:9289–9297. [PubMed: 10531433]
- Korpi ER, Grunder G, Luddens H. Drug interactions at GABA(A) receptors. *Prog. Neurobiol.* 2002a; 67:113–159. [PubMed: 12126658]
- Korpi ER, Koikkalainen P, Vekovischeva OY, Makela R, Kleinz R, Uusi-Oukari M, Wisden W. Cerebellar granule-cell-specific GABA<sub>A</sub> receptors attenuate benzodiazepine-induced ataxia:

- evidence from alpha 6-subunit-deficient mice. *Eur. J. Neurosci.* 1999; 11:233–240. [PubMed: 9987027]
- Korpi ER, Mihalek RM, Sinkkonen ST, Hauer B, Hevers W, Homanics GE, Sieghart W, Luddens H. Altered receptor subtypes in the forebrain of GABA(A) receptor delta subunit-deficient mice: recruitment of gamma 2 subunits. *Neuroscience.* 2002b; 109:733–743. [PubMed: 11927155]
- Kralic JE, Sidler C, Parpan F, Homanics GE, Morrow AL, Fritschy JM. Compensatory alteration of inhibitory synaptic circuits in cerebellum and thalamus of gamma-aminobutyric acid type A receptor alpha1 subunit knockout mice. *J. Comp. Neurol.* 2006; 495:408–421. [PubMed: 16485284]
- Krasowski MD, Harrison NL. General anaesthetic actions on ligand-gated ion channels. *Cell Mol. Life Sci.* 1999; 55:1278–1303. [PubMed: 10487207]
- Kukhtina V, Kottwitz D, Strauss H, Heise B, Chebotareva N, Tsetlin V, Hucho F. Intracellular domain of nicotinic acetylcholine receptor: the importance of being unfolded. *J. Neurochem.* 2006; 97:63–67. [PubMed: 16635251]
- Laurie DJ, Seeburg PH, Wisden W. The distribution of 13 GABA<sub>A</sub> receptor subunit mRNAs in the rat brain. II. Olfactory bulb and cerebellum. *J. Neurosci.* 1992a; 12:1063–1076. [PubMed: 1312132]
- Laurie DJ, Wisden W, Seeburg PH. The distribution of thirteen GABA<sub>A</sub> receptor subunit mRNAs in the rat brain. III. Embryonic and postnatal development. *J. Neurosci.* 1992b; 12:4151–4172. [PubMed: 1331359]
- Lavoie AM, Tingey JJ, Harrison NL, Pritchett DB, Twyman RE. Activation and deactivation rates of recombinant GABA(A) receptor channels are dependent on alpha-subunit isoform. *Biophys. J.* 1997; 73:2518–2526. [PubMed: 9370445]
- Lee WY, Sine SM. Principal pathway coupling agonist binding to channel gating in nicotinic receptors. *Nature.* 2005; 438:243–247. [PubMed: 16281039]
- Lester HA, Dibas MI, Dahan DS, Leite JF, Dougherty DA. Cys-loop receptors: new twists and turns. *Trends Neurosci.* 2004; 27:329–336. [PubMed: 15165737]
- Levi S, Logan SM, Tovar KR, Craig AM. Gephyrin is critical for glycine receptor clustering but not for the formation of functional GABAergic synapses in hippocampal neurons. *J. Neurosci.* 2004; 24:207–217. [PubMed: 14715953]
- Liu F, Wan Q, Pristupa ZB, Yu XM, Wang YT, Niznik HB. Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors. *Nature.* 2000; 403:274–280. [PubMed: 10659839]
- Luddens H, Pritchett DB, Kohler M, Killisch I, Keinanen K, Monyer H, Sprengel R, Seeburg PH. Cerebellar GABA<sub>A</sub> receptor selective for a behavioural alcohol antagonist. *Nature.* 1990; 346:648–651. [PubMed: 2166916]
- Lummis SC, Beene DL, Lee LW, Lester HA, Broadhurst RW, Dougherty DA. Cis-trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel. *Nature.* 2005; 438:248–252. [PubMed: 16281040]
- Luscher B, Keller CA. Regulation of GABA<sub>A</sub> receptor trafficking, channel activity, and functional plasticity of inhibitory synapses. *Pharmacol. Ther.* 2004; 102:195–221. [PubMed: 15246246]
- Macdonald, RL.; Haas, KF. Kinetic Properties of GABA<sub>A</sub> Receptor Channels. In: Martin, DL.; Olsen, RW., editors. *GABA in the Nervous System: The View at Fifty Years*. Lippincott Williams and Wilkins; Philadelphia: 2000. p. 141-165.
- Mathie A, Sutton GL, Clarke CE, Veale EL. Zinc and copper: pharmacological probes and endogenous modulators of neuronal excitability. *Pharmacol Ther.* 2006; 111:567–583. [PubMed: 16410023]
- McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, Farrar S, Myers J, Cook G, Ferris P, Garrett L, Bristow L, Marshall G, Macaulay A, Brown N, Howell O, Moore KW, Carling RW, Street LJ, Castro JL, Ragan CI, Dawson GR, Whiting PJ. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. *Nat. Neurosci.* 2000; 3:587–592. [PubMed: 10816315]
- Mellor JR, Randall AD. Frequency-dependent actions of benzodiazepines on GABA<sub>A</sub> receptors in cultured murine cerebellar granule cells. *J. Physiol.* 1997; 503:353–369. [PubMed: 9306278]
- Mihalek RM, Banerjee PK, Korpi ER, Quinlan JJ, Firestone LL, Mi ZP, Lagenaur C, Tretter V, Sieghart W, Anagnostaras SG, Sage JR, Fanselow MS, Guidotti A, Spigelman I, Li Z, DeLorey


- TM, Olsen RW, Homanics GE. Attenuated sensitivity to neuroactive steroids in gamma-aminobutyrate type A receptor delta subunit knockout mice. *Proc. Natl. Acad. Sci. USA.* 1999; 96:12905–12910. [PubMed: 10536021]
- Misgeld U. Innervation of the substantia nigra. *Cell Tissue Res.* 2004; 318:107–114. [PubMed: 15338269]
- Mody I, Pearce RA. Diversity of inhibitory neurotransmission through GABA<sub>A</sub> receptors. *Trends Neurosci.* 2004; 27:569–575. [PubMed: 15331240]
- Moragues N, Ciofi P, Tramu G, Garret M. Localisation of GABA(A) receptor epsilon-subunit in cholinergic and aminergic neurones and evidence for co-distribution with the theta-subunit in rat brain. *Neuroscience.* 2002; 111:657–669. [PubMed: 12031352]
- Niddam R, Dubois A, Scatton B, Arbilla S, Langer SZ. Autoradiographic localization of [<sup>3</sup>H]zolpidem binding sites in the rat CNS: comparison with the distribution of [<sup>3</sup>H]flunitrazepam binding sites. *J. Neurochem.* 1987; 49:890–899. [PubMed: 3039057]
- Nusser Z. A new approach to estimate the number, density and variability of receptors at central synapses. *Eur. J. Neurosci.* 1999; 11:745–752. [PubMed: 10103068]
- Nusser Z, Sieghart W, Somogyi P. Segregation of different GABA<sub>A</sub> receptors to synaptic and extrasynaptic membranes of cerebellar granule cells. *J. Neurosci.* 1998; 18:1693–1703. [PubMed: 9464994]
- Nyiri G, Freund TF, Somogyi P. Input-dependent synaptic targeting of alpha(2)-subunit-containing GABA(A) receptors in synapses of hippocampal pyramidal cells of the rat. *Eur. J. Neurosci.* 2001; 13:428–442. [PubMed: 11168550]
- Ogris W, Poltl A, Hauer B, Ernst M, Oberto A, Wulff P, Hoyer H, Wisden W, Sieghart W. Affinity of various benzodiazepine site ligands in mice with a point mutation in the GABA(A) receptor gamma2 subunit. *Biochem. Pharmacol.* 2004; 68:1621–1629. [PubMed: 15451405]
- Okada H, Matsushita N, Kobayashi K, Kobayashi K. Identification of GABA<sub>A</sub> receptor subunit variants in midbrain dopaminergic neurons. *J. Neurochem.* 2004; 89:7–14. [PubMed: 15030384]
- Olsen RW, Chang CS, Li G, Hancher HJ, Wallner M. Fishing for allosteric sites on GABA(A) receptors. *Biochem. Pharmacol.* 2004; 68:1675–1684. [PubMed: 15451411]
- Olsen RW, McCabe RT, Wamsley JK. GABA<sub>A</sub> receptor subtypes: autoradiographic comparison of GABA, benzodiazepine, and convulsant binding sites in the rat central nervous system. *J. Chem. Neuroanat.* 1990; 3:59–76. [PubMed: 2156526]
- Peng Z, Hauer B, Mihalek RM, Homanics GE, Sieghart W, Olsen RW, Houser CR. GABA(A) receptor changes in delta subunit-deficient mice: altered expression of alpha4 and gamma2 subunits in the forebrain. *J. Comp. Neurol.* 2002; 446:179–197. [PubMed: 11932935]
- Persohn E, Malherbe P, Richards JG. Comparative molecular neuroanatomy of cloned GABA<sub>A</sub> receptor subunits in the rat CNS. *J. Comp. Neurol.* 1992; 326:193–216. [PubMed: 1336019]
- Peters JA, Hales TG, Lambert JJ. Molecular determinants of single channel conductance and ion selectivity in the Cys-loop family: insights from the 5-HT<sub>3</sub> receptor. *Trends Pharmacol. Sci.* 2005; 26:587–594. [PubMed: 16194573]
- Petri S, Krampfl K, Dengler R, Bufler J, Weindl A, Arzberger T. Human GABA<sub>A</sub> receptors on dopaminergic neurons in the pars compacta of the substantia nigra. *J. Comp. Neurol.* 2002; 452:360–366. [PubMed: 12355418]
- Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, Sperk G. GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. *Neuroscience.* 2000; 101:815–850. [PubMed: 11113332]
- Pritchett DB, Luddens H, Seeburg PH. Type I and type II GABA<sub>A</sub>-benzodiazepine receptors produced in transfected cells. *Science.* 1989; 245:1389–1392. [PubMed: 2551039]
- Ramming M, Kins S, Werner N, Hermann A, Betz H, Kirsch J. Diversity and phylogeny of gephyrin: tissue-specific splice variants, gene structure, and sequence similarities to molybdenum cofactor-synthesizing and cytoskeleton-associated proteins. *Proc. Natl. Acad. Sci. USA.* 2000; 97:10266–10271. [PubMed: 10963686]
- Rathenberg J, Kittler JT, Moss SJ. Palmitoylation regulates the clustering and cell surface stability of GABA<sub>A</sub> receptors. *Mol. Cell Neurosci.* 2004; 26:251–257. [PubMed: 15207850]

- Reynolds DS, Rosahl TW, Cirone J, O'Meara GF, Haythornthwaite A, Newman RJ, Myers J, Sur C, Howell O, Rutter AR, Atack J, Macaulay AJ, Hadingham KL, Hutson PH, Belelli D, Lambert JJ, Dawson GR, McKernan R, Whiting PJ, Wafford KA. Sedation and anesthesia mediated by distinct GABA(A) receptor isoforms. *J. Neurosci.* 2003; 23:8608–8617. [PubMed: 13679430]
- Rivera C, Voipio J, Kaila K. Two developmental switches in GABAergic signalling: the K<sup>+</sup>-Cl<sup>-</sup> cotransporter KCC2 and carbonic anhydrase CAVII. *J. Physiol.* 2005; 562:27–36. [PubMed: 15528236]
- Rowlett JK, Platt DM, Lelas S, Atack JR, Dawson GR. Different GABA<sub>A</sub> receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. *Proc. Natl. Acad. Sci. USA.* 2005; 102:915–920. [PubMed: 15644443]
- Rudolph U, Moehler H. GABA-based therapeutic approaches: GABA<sub>A</sub> receptor subtype functions. *Curr. Opin. Pharmacol.* 2006; 6:18–23. [PubMed: 16376150]
- Rudolph U, Mohler H. Analysis of GABA<sub>A</sub> receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. *Annu. Rev. Pharmacol. Toxicol.* 2004; 44:475–498. [PubMed: 14744255]
- Saper CB, Sawchenko PE. Magic peptides, magic antibodies: guidelines for appropriate controls for immunohistochemistry. *J. Comp. Neurol.* 2003; 465:161–163. [PubMed: 12949777]
- Schofield PR, Darlison MG, Fujita N, Burt DR, Stephenson FA, Rodriguez H, Rhee LM, Ramachandran J, Reale V, Glencorse TA, et al. Sequence and functional expression of the GABA<sub>A</sub> receptor shows a ligand-gated receptor super-family. *Nature.* 1987; 328:221–227. [PubMed: 3037384]
- Schwarzer C, Berresheim U, Pirker S, Wieselthaler A, Fuchs K, Sieghart W, Sperk G. Distribution of the major gamma-aminobutyric acid(A) receptor subunits in the basal ganglia and associated limbic brain areas of the adult rat. *J. Comp. Neurol.* 2001; 433:526–549. [PubMed: 11304716]
- Schweizer C, Balsiger S, Bluethmann H, Mansuy IM, Fritschy JM, Mohler H, Luscher B. The gamma 2 subunit of GABA(A) receptors is required for maintenance of receptors at mature synapses. *Mol. Cell. Neurosci.* 2003; 24:442–450. [PubMed: 14572465]
- Seeburg PH, Wisden W, Verdoorn TA, Pritchett DB, Werner P, Herb A, Luddens H, Sprengel R, Sakmann B. The GABA<sub>A</sub> receptor family: molecular and functional diversity. *Cold Spring Harb. Symp. Quant. Biol.* 1990; 55:29–40. [PubMed: 1966765]
- Semyanov A, Walker MC, Kullmann DM, Silver RA. Tonically active GABA<sub>A</sub> receptors: modulating gain and maintaining the tone. *Trends Neurosci.* 2004; 27:262–269. [PubMed: 15111008]
- Sieghart W, Sperk G. Subunit composition, distribution and function of GABA(A) receptor subtypes. *Curr. Top. Med. Chem.* 2002; 2:795–816. [PubMed: 12171572]
- Sigel E, Buhr A. The benzodiazepine binding site of GABA<sub>A</sub> receptors. *Trends Pharmacol. Sci.* 1997; 18:425–429. [PubMed: 9426470]
- Simon J, Wakimoto H, Fujita N, Lalande M, Barnard EA. Analysis of the set of GABA<sub>A</sub> receptor genes in the human genome. *J. Biol. Chem.* 2004; 279:41422–41435. [PubMed: 15258161]
- Sinkkonen ST, Hanna MC, Kirkness EF, Korpi ER. GABA(A) receptor epsilon and theta subunits display unusual structural variation between species and are enriched in the rat locus ceruleus. *J. Neurosci.* 2000; 20:3588–3595. [PubMed: 10804200]
- Smith Y, Bevan MD, Shink E, Bolam JP. Microcircuitry of the direct and indirect pathways of the basal ganglia. *Neuroscience.* 1998; 86:353–387. [PubMed: 9881853]
- Somogyi P, Fritschy JM, Benke D, Roberts JD, Sieghart W. The gamma2 subunit of the GABA<sub>A</sub> receptor is concentrated in synaptic junctions containing the alpha1 and beta2/3 subunits in hippocampus, cerebellum and globus pallidus. *Neuropharmacology.* 1996; 35:1425–1444. [PubMed: 9014159]
- Staley K, Scharfmann H. A woman's prerogative. *Nat. Neurosci.* 2005; 8:697–699. [PubMed: 15917829]
- Stell BM, Brickley SG, Tang CY, Farrant M, Mody I. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABA<sub>A</sub> receptors. *Proc. Natl. Acad. Sci. USA.* 2003; 100:14439–14444. [PubMed: 14623958]


- Sundstrom-Poromaa I, Smith DH, Gong QH, Sabado TN, Li X, Light A, Wiedmann M, Williams K, Smith SS. Hormonally regulated alpha(4)beta(2)delta GABA(A) receptors are a target for alcohol. *Nat. Neurosci.* 2002; 5:721–722. [PubMed: 12118257]
- Szabadics J, Varga C, Molnar G, Olah S, Barzo P, Tamas G. Excitatory effect of GABAergic axo-axonic cells in cortical microcircuits. *Science.* 2006; 311:233–235. [PubMed: 16410524]
- Tepper JM, Bolam JP. Functional diversity and specificity of neostriatal interneurons. *Curr. Opin. Neurobiol.* 2004; 14:685–692. [PubMed: 15582369]
- Thomas P, Martensen M, Hosie AM, Smart TG. Dynamic mobility of functional GABA<sub>A</sub> receptors at inhibitory synapses. *Nat. Neurosci.* 2005; 8:889–897. [PubMed: 15951809]
- Thompson SA, Wafford K. Mechanism of action of general anaesthetics—new information from molecular pharmacology. *Curr. Opin. Pharmacol.* 2001; 1:78–83. [PubMed: 11712540]
- Thomson AM, Bannister AP, Hughes DI, Pawelzik H. Differential sensitivity to Zolpidem of IPSPs activated by morphologically identified CA1 interneurons in slices of rat hippocampus. *Eur. J. Neurosci.* 2000; 12:425–436. [PubMed: 10712623]
- Tretter V, Hauer B, Nusser Z, Mihalek RM, Hoger H, Homanics GE, Somogyi P, Sieghart W. Targeted disruption of the GABA(A) receptor delta subunit gene leads to an up-regulation of gamma 2 subunit-containing receptors in cerebellar granule cells. *J. Biol. Chem.* 2001; 276:10532–10538. [PubMed: 11136737]
- Unwin N. Structure and action of the nicotinic acetylcholine receptor explored by electron microscopy. *FEBS Lett.* 2003; 555:91–95. [PubMed: 14630325]
- Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4A resolution. *J. Mol. Biol.* 2005; 346:967–989. [PubMed: 15701510]
- Vicini S, Ortinski P. Genetic manipulations of GABA<sub>A</sub> receptor in mice make inhibition exciting. *Pharmacol. Ther.* 2004; 103:109–120. [PubMed: 15369679]
- Waldvogel HJ, Kubota Y, Fritschy J, Mohler H, Faull RL. Regional and cellular localisation of GABA(A) receptor subunits in the human basal ganglia: An autoradiographic and immunohistochemical study. *J. Comp. Neurol.* 1999; 415:313–340. [PubMed: 10553118]
- Wallner M, Hancher HJ, Olsen RW. Ethanol enhances alpha 4 beta 3 delta and alpha 6 beta 3 delta gamma-aminobutyric acid type A receptors at low concentrations known to affect humans. *Proc. Natl. Acad. Sci. USA.* 2003; 100:5218–15223.
- Wang Q, Liu L, Pei L, Ju W, Ahmadian G, Lu J, Wang Y, Liu F, Wang YT. Control of synaptic strength, a novel function of Akt. *Neuron.* 2003; 38:915–928. [PubMed: 12818177]
- Wang X, Zhong P, Yan Z. Dopamine D4 receptors modulate GABAergic signaling in pyramidal neurons of prefrontal cortex. *J. Neurosci.* 2002; 22:9185–9193. [PubMed: 12417643]
- Wei W, Zhang N, Peng Z, Houser CR, Mody I. Perisynaptic localization of delta subunit-containing GABA(A) receptors and their activation by GABA spillover in the mouse dentate gyrus. *J. Neurosci.* 2003; 23:10650–10661. [PubMed: 14627650]
- Whiting PJ. GABA<sub>A</sub> receptors: a viable target for novel anxiolytics? *Curr. Opin. Pharmacol.* 2006; 6:24–29. [PubMed: 16359919]
- Wieland HA, Luddens H, Seeburg PH. A single histidine in GABA<sub>A</sub> receptors is essential for benzodiazepine agonist binding. *J. Biol. Chem.* 1992; 267:1426–1429. [PubMed: 1346133]
- Wingrove PB, Thompson SA, Wafford KA, Whiting PJ. Key amino acids in the gamma subunit of the gamma-aminobutyric acidA receptor that determine ligand binding and modulation at the benzodiazepine site. *Mol Pharmacol.* 1997; 52:874–881. [PubMed: 9351978]
- Wisden W, Cope D, Klausberger T, Hauer B, Sinkkonen ST, Tretter V, Lujan R, Jones A, Korpi ER, Mody I, Sieghart W, Somogyi P. Ectopic expression of the GABA(A) receptor alpha6 subunit in hippocampal pyramidal neurons produces extrasynaptic receptors and an increased tonic inhibition. *Neuropharmacology.* 2002; 43:530–549. [PubMed: 12367600]
- Wisden W, Herb A, Wieland H, Keinänen K, Luddens H, Seeburg PH. Cloning, pharmacological characteristics and expression pattern of the rat GABA<sub>A</sub> receptor alpha 4 subunit. *FEBS Lett.* 1991; 289:227–230. [PubMed: 1655526]
- Wisden W, Laurie DJ, Monyer H, Seeburg PH. The distribution of 13 GABA<sub>A</sub> receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. *J. Neurosci.* 1992; 12:1040–1062. [PubMed: 1312131]

- Wisden W, Morris BJ, Darlison MG, Hunt SP, Barnard EA. Localization of GABA<sub>A</sub> receptor alpha-subunit mRNAs in relation to receptor subtypes. *Mol. Brain Res.* 1989; 5:305–310. [PubMed: 2546001]
- Wohlfarth KM, Bianchi MT, Macdonald RL. Enhanced neurosteroid potentiation of ternary GABA(A) receptors containing the delta subunit. *J. Neurosci.* 2002; 22:1541–1549. [PubMed: 11880484]
- Xiu X, Hanek AP, Wang J, Lester HA, Dougherty DA. A unified view of the role of electrostatic interactions in modulating the gating of Cys loop receptors. *J. Biol. Chem.* 2005; 280:41655–41666. [PubMed: 16216879]
- Yee BK, Keist R, von Boehmer L, Studer R, Benke D, Hagenbuch N, Dong Y, Malenka RC, Fritschy JM, Bluethmann H, Feldon J, Mohler H, Rudolph U. A schizophrenia-related sensorimotor deficit links alpha 3-containing GABA<sub>A</sub> receptors to a dopamine hyperfunction. *Proc. Natl. Acad. Sci. USA.* 2005; 102:17154–17159. [PubMed: 16284244]






**Fig. 1.** Predicted topology of a GABA<sub>A</sub> receptor subunit. The cysteine-disulfide bridge in the N-terminus is indicated by a black bar. Transmembrane domains are shown as open boxes labelled TM1-4.



**Fig. 2.** Model of the extracellular domains of a pentameric GABA<sub>A</sub> receptor consisting of two  $\alpha$ , two  $\beta$  and one  $\gamma 2$  subunit. (a) View from the extracellular space. GABA binds to the interface between the  $\alpha$  and the  $\beta$  subunit, benzodiazepines bind to the interface between the  $\alpha$  and the  $\gamma 2$  subunit. (b) Predicted benzodiazepine-binding pocket between the  $\alpha$  and the  $\gamma 2$  subunit, viewed from the side. The binding site loops are labelled A to G. (c) and (d) The  $\alpha$  and  $\beta$  subunit viewed from the side. Loops A, B, C, D and E form the predicted GABA-binding pocket (blue volume in (d)). The volume shown in green might be used in antagonist-bound states. (Adapted from Ernst et al., 2003 used with permission.)



**Fig. 3.** Phasic and tonic GABAergic inhibition. Fast synaptic (phasic) inhibition is mediated mainly via  $\gamma_2$  subunit-containing receptors (shown in black).  $\delta$  subunit-containing receptors (shown in grey) are located peri- or extrasynaptically and are tonically activated by GABA diffusing out of the synaptic cleft.